

# INDEX

- Abecarnil, GABA<sub>A</sub> subunit pharmacology,  
allosteric ligand modulation,  
503–506
- Acetylcholine (ACh)  
action potential research on, 26–27  
early research on, 17  
Feldberg's research on, 20–21  
H<sub>3</sub> receptor release, 316  
Loewi's experiments in, 18–19  
muscarinic receptors  
activation mechanisms, 155  
dimerization, 166–167  
distribution, 149  
G-proteing coupling properties,  
155–156  
RGS proteins, 158  
ion channels, 160–162  
ligand binding mechanisms, 152–154  
agonists, 152  
allosteric ligands, 153–154  
antagonists, 152–153  
clinical applications, 154  
MAPK pathways modulation, 159  
phenotypic mouse analysis, 167–177  
agonist-induced tremor and  
hypothermia, 170–171  
amylase secretion, exocrine pancreas,  
175  
analgesia, 170  
autoreceptors, 171  
cardiovascular system, 175–176  
cytolytic T cells, 177  
drug abuse effects, 173  
epileptic seizures, 169  
food intake stimulation, 171  
gastric acid secretion, 175  
inhibitory hippocampal synapse  
suppression, 172  
learning and memory functions,  
168–169  
locomotor activity, 169–170  
nucleus accumbens, dopamine effects,  
172–173  
pancreatic islet insulin and glucagon  
secretion, 174–175  
peripheral autoreceptors and  
heteroreceptors, 176  
prepulse inhibition and  
haloperidol-induced catalepsy,  
172  
salivary secretion, 174  
skin functions, 177  
smooth muscle functions, 173–174  
striatal dopamine release modulation,  
171–172  
regulatory mechanisms, 162–166  
downregulation, 163–164  
internatizations, 162–163  
phosphorylation, 164–166  
resensitization, 166  
uncoupling, 162  
research background, 148–149

- signaling pathways, 158–159
  - structural features, 149–151
- neuropeptide electrophysiology and, 676–677
- neurotransmitter transporters
  - choline, 714–715
  - vesicular transporters, 716–717
- Torpedo electric organ, 109–110
- transmitter inactivation, 51–52
- Acetylcholine binding protein (AChBP),
  - GABA<sub>A</sub> receptor activation, agonist binding site architecture, 495
- Acetylcholinesterase
  - early research on, 23
  - nicotinic acetylcholine receptor and, 28
- Action potentials
  - early research on, 25–27
  - voltage-gated potassium channels, K<sub>V</sub> subunits, structure and function, 628–630
- Activin, vascular endothelial growth factor and, 809
- Addiction. *See* Substance abuse
- Adenosine diphosphate (ADP) ribosylation factor (ARF) family, GABA<sub>B</sub> receptor trafficking and heteromization, 577–578
- Adenosine triphosphate (ATP)
  - plasma membrane glutamate transporters, 709–711
  - second messengers and, 31–32
  - synapse research and, 23
- Adenylate cyclase
  - GABA<sub>B</sub> receptors, effector systems, 582–583
  - H<sub>3</sub> receptor, 314–315
  - lithium mechanism in bipolar disorder patients, 868–869
- Adenylyl cyclase (AC)
  - α<sub>2</sub> adrenergic receptor regulation, signal transduction pathways, 206
  - cyclic nucleotide second messenger signaling, 72–77
  - heterotrimeric G proteins, 62–63
  - muscarinic acetylcholine receptors, G-protein-coupling properties, 156
- Adrenaline, early research on, 15–16
- Adrenergic receptors. *See also* α and β-adrenergic receptors
  - historical perspective, 194–195
- α-adrenergic receptors
  - α<sub>1</sub>-adrenergic receptor
    - general characteristics, 201–203
    - physiological roles, 203–204
    - signal transduction pathways, 203
  - α<sub>2</sub>-adrenergic receptor
    - general characteristics, 204–206
    - physiological roles, 207–209
    - signal transduction pathways, 206
  - historical perspective, 196
  - subdivision of, 196
- β-adrenergic receptors
  - general characteristics and regulation, 209–210
  - physiological roles, 211–213
  - signal transduction pathways, 210–211
  - subdivision of, 195–196
- Adrenergic transmitters, early research on, 29–30
- Adrenocorticotrophic hormone (ACTH), neuropeptides and, 670–671
  - behavioral techniques, 677–678
  - opioid family gene duplication, 680–682
- Afferents, histaminergic neurons, 303–305
- Affinity mechanisms, GABA<sub>A</sub> receptors, desensitization and deactivation, 498–499
- Afterhyperpolarization (AHP), small-conductance calcium-activated potassium channels, 631–632
- Agatoxins, voltage-gated calcium ion channels, Ca<sub>v</sub>2 family, 649
- Agonist chelation hypothesis, GABA<sub>A</sub> receptor activation, 493–494
  - binding site architecture, 494–495
- Agonists
  - α<sub>1</sub> adrenergic receptors, 202–203
  - GABA<sub>A</sub> receptor activation, 492–495
    - allosteric ligand modulation, 500–506
    - glutamate transporter regulation, 728
    - muscarinic acetylcholine receptor, ligand binding, 152
    - neuropeptide receptors, 675
    - serotonin receptor families, 263–267
    - upregulation, nicotinic acetylcholine receptor, 127–130
- A kinase anchoring proteins (AKAPs), GABA<sub>A</sub> phosphorylation, 482
- Alcohols, GABA<sub>A</sub> receptor modulation, 511–516

- Aldo-keto reductase family, voltage-gated potassium channels, 627–628
- Allopregnanolone, GABA<sub>A</sub> receptor modulation, 515
- Allosteric ligands
- GABA<sub>A</sub> receptor modulation
    - benzodiazepine recognition site, 499–506
    - benzodiazepine structural determinants, 507–509
    - transmembrane domains, 516–518
    - unidentified sites, 519–520
  - GABA<sub>B</sub> receptor subunits, 580
  - muscarinic acetylcholine receptor, 153–154
- Allosteric potentiators and antagonists
- GABA<sub>B</sub> receptors, 590–592
  - ionotropic glutamate receptors, 385–397
    - AMPA antagonists, 395–396
    - AMPA potentiators, 390–395
    - kainate receptor antagonists, 397
    - kainate receptor potentiators, 396
    - NMDA receptor antagonists, 386–390
    - NMDA receptor potentiators, 385–386
  - metabotropic glutamate receptors
    - mGlu1 antagonists, 436–437
    - mGlu2/3 antagonists, 439–440
    - mGlu5 antagonists, 443–445
    - mGlu7 antagonists, 445
    - mGlu1 potentiators, 435–436
    - mGlu2 potentiators, 437–439
    - mGlu4 potentiators, 440–441
    - mGlu5 potentiators, 441–443
- $\alpha_1$  interaction domain (AID), voltage-gated calcium channels, 644
- Alzheimer's disease
- dopaminergic drugs, 237
  - GABA<sub>A</sub>  $\alpha_5$  subunit pharmacology, 489
  - histaminergic neuron activity, 327–328
  - KCNQ channels and, 633
  - nitric oxide and, 754
  - plasma membrane glutamate transporter, 719
- Amino acid residues, GABA<sub>A</sub> receptors
- activation, agonist binding site architecture, 494–495
  - assembly, 478
  - modulation, allosteric structural determinants, 508–509
- Amino acid transmitters
- early research on, 32
  - intercellular signaling and, 42–44
- 1-Amino-cyclopentane-1,3-dicarboxylic acid (ACPD), mGlu group I selective orthosteric agonists, 423
- Aminocyclopropylcarboxylic acid (ACC), NMDA allosteric potentiators, 386
- (*R,S*)-1-Aminoindan-1,5-dicarboxylic acid (AIDA), mGlu I selective orthosteric antagonists, 425
- 2*R,4R*-4-Aminopyrrolidine-2,4-dicarboxylate (2*R,4R*-APDC), mGlu II selective orthosteric agonists, 429
- AMPA receptors
- allosteric antagonists, 395–396
  - allosteric potentiators, 390–395
  - kainate receptor orthosteric agonists, 381
  - mGlu group I selective orthosteric agonists, quisqualate, 423
  - orthosteric agonists, 376–377
  - orthosteric antagonists, 377–378
  - structure and function, 370–371
- Amphetamine derivatives, serotonin synthesis, 261
- Amylase secretion, exocrine pancreas, muscarinic acetylcholine receptor deficiency, 175
- Amyotrophic lateral sclerosis (ALS)
- nitric oxide and, 754
  - plasma membrane glutamate transporter, 718–719
- Analgesia
- $\alpha_2$  adrenergic receptor physiology, 207–208
  - muscarinic acetylcholine receptor deficiency, 170
- Anesthesias
- GABA<sub>A</sub>  $\beta$  subunit pharmacology, 490–491
  - GABA<sub>A</sub> receptor modulation, 511–516
  - voltage-gated sodium ion channels and, 643
- Angina therapy, voltage-gated calcium channels, Ca<sub>v</sub>1 family, 648
- Angiotensin-converting enzyme (ACE), neuropeptide inactivation, 687–688
- Animal models
- antidepressants and hippocampal neurogenesis, 833
  - curare research on, 5–7
  - pharmacology research and, 11
- Aniracetam, AMPA receptor allosteric potentiators, 390–391

- Antagonists
- GABA<sub>A</sub> receptor activation, 492–495
    - allosteric ligand modulation, 500–506
  - GABA<sub>B</sub> receptors, 590
  - glutamate transporter regulation, 728
  - muscarinic acetylcholine receptor, ligand binding, 152–153
  - neuropeptide receptors, 675
- Antianxiety drugs
- GABA<sub>A</sub> subunit pharmacology
    - allosteric ligand modulation, 503–506
    - $\alpha$  subunits, 483–490, 509–511
      - $\alpha_1$  subunit, 484, 488
      - $\alpha_2$  subunit, 488
      - $\alpha_3$  subunit, 488
      - $\alpha_4$  subunit, 488–489
      - $\alpha_5$  subunit, 489
      - $\alpha_6$  subunit, 489–490
    - electrophysiology, 486–487
    - modulator selectivity, 484
    - terminology, 483
  - GABA<sub>B</sub> receptor targeting, 594–595
  - 5-HT<sub>2C</sub> receptors and, 272–273
  - mGlu5 allosteric antagonists, 443–444
  - mGlu2 allosteric potentiators, 439
  - mGlu II selective orthosteric agonists, 427–429
  - mGlu II selective orthosteric antagonists, 430–431
  - serotonin receptors, 263–266
- Antiarrhythmics
- KCNH potassium channels, 634
  - voltage-gated calcium channels, Ca<sub>v</sub>1 family, 648
  - voltage-gated sodium ion channels and, 642
- Anticonvulsant drugs
- AMPA receptor allosteric antagonists, 396
  - in bipolar disorder patients, 869–870
  - GABA<sub>A</sub>  $\alpha_1$  subunit pharmacology, 484–485, 488
  - GABA<sub>A</sub> receptor modulation, 511–516
  - GABA<sub>B</sub> receptor targeting, 595
  - histamine neuron physiology, 326
  - mGlu II selective orthosteric agonists, 428–429
  - mGlu I selective orthosteric antagonists, 425–426
- Antidepressants
- $\beta$ -adrenergic receptor activation, 210
  - GABA<sub>B</sub> receptor targeting, 594–595
  - hippocampal neurogenesis and
    - adult neurogenesis stages, 827–828
    - behavioral and animal models, 833
    - depression physiology and, 823–824, 826–827
    - future research on, 833
    - monoamines and, 822–823
    - research background, 821–822
    - serotonin/norepinephrine regulation, 831–833
    - stress and monamine hypotheses, 825–826
    - stress hormone neurogenesis regulation, 829–830
  - histaminergic neuron activity, 329
  - 5-HT<sub>2C</sub> receptors and, 272–273
  - mGlu II selective orthosteric antagonists, 431
  - neurotrophic factor expression and, 804–806
    - BDNF expression, 804–805
    - models for, 805–806
    - neurogenesis in adults and, 806–808
    - serotonin receptors, 263–266
- Antidiabetic agents,  $\beta$ -adrenergic receptor physiology, 212–213
- Antidiuretic hormone (ADH). *See* Vasopressin
- Antihistamines
- arousal mechanisms, 323–324
  - KCNH potassium channels, 634
- Antiobesity agents,  $\beta$ -adrenergic receptor physiology, 212–213
- Antipsychotic drugs
- $\alpha_2$ -adrenergic receptor physiology, 209
  - in bipolar disorder patients, 869–870
  - histaminergic neuron activity, 327
  - 5-HT<sub>6</sub> receptor family and, 275
  - mGlu2 allosteric potentiators, 439
  - mGlu II selective orthosteric agonists, 427–429
- Anxiety
- histaminergic neuron activity, 329
  - 5-HT<sub>2B</sub> receptors and, 271
  - serotonin transporters and, 720
- Apamin, small-conductance calcium-activated potassium channels, 632
- AP-1 complex, amino acid neurotransmitters, 44
- Appetite regulation
- histaminergic neuron activity, 325–326

- 5-HT<sub>2C</sub> receptors and, 272–273  
 muscarinic acetylcholine receptor deficiency, 171
- Arginine vasopressin, neuropeptide receptors, 689
- Aromatic amino acid decarboxylase (AAAD)  
 dopamine synthesis, 223–224  
 serotonin synthesis, 260–261
- Arousal, histamine neuron physiology, 322–324
- Arrhythmias  
 KCNH potassium channels, 634  
 voltage-gated calcium channels, Ca<sub>v</sub>1 family, 648  
 voltage-gated sodium ion channels and, 642
- 2-Arylureidobenzoic acids, kainate receptor allosteric antagonists, 397
- Assembly mechanisms, GABA<sub>A</sub> receptor assembly, 477–478
- ATPA, kainate receptor orthosteric agonists, 381
- Atropine, early research on, 10
- Attention-deficit hyperactivity disorder (ADHD)  
 dopaminergic drugs, 237–238  
 dopamine transporters and, 721  
 GABA<sub>B</sub> receptor targeting, 592–593  
 histaminergic neuron activity, 329
- Auditory function, KCNQ channel action on, 632–633
- Autism  
 dopaminergic drugs, 237  
 serotonin transporters and, 720
- Autoimmune diseases, nitric oxide physiology, 745
- Autonomic nervous system, early research on, 13
- Autoradiography, neuropeptide identification, 673–674
- Autoreceptors  
 chemical transmission, 50–51  
 H<sub>3</sub> receptor, 314–315  
 muscarinic acetylcholine receptor deficiency, 171  
 peripheral agents, 176  
 serotonin receptor families, 263–267
- Backpropagation action potentials, voltage-gated potassium channels, K<sub>v</sub> subunits, structure and function, 629–630
- Baclofen  
 GABA<sub>B</sub> receptors, 469  
 anxiety and depression therapy, 594–595  
 targeting, 592–593
- Barium  
 second messengers and, 31–32  
 voltage-gated potassium channels, K<sub>v</sub> subunits, structure and function, 630
- BAY367620, mGlu1 allosteric antagonists, 437
- Behavioral techniques  
 antidepressants and hippocampal neurogenesis, 833  
 neuropeptide electrophysiology and, 677–678  
 neurotrophic factors and, 808–809
- Benign neonatal familial convulsion (BNFC), KCNQ channels and, 633
- Benzamides  
 AMPA receptor allosteric potentiators, 390  
 NMDA receptor allosteric antagonists, 390
- Benzimidazoles, NMDA receptor allosteric antagonists, 390
- Benzodiazepine  
 GABA<sub>A</sub> receptor modulation  
 allosteric binding, 499–506  
 allosteric structural determinants, 507–509  
 binding sites, 506–507  
 GABA<sub>A</sub> subunit pharmacology  
 α subunits, 483–490, 509–511  
 α<sub>1</sub> subunit, 484, 488  
 α<sub>2</sub> subunit, 488  
 α<sub>3</sub> subunit, 488  
 α<sub>4</sub> subunit, 488–489  
 α<sub>5</sub> subunit, 489  
 α<sub>6</sub> subunit, 489–490  
 electrophysiology, 486–487  
 modulator selectivity, 484  
 γ subunit isoforms, 509–511  
 terminology, 483
- 2,3-Benzodiazepine, AMPA receptor allosteric antagonists, 395
- Benzothiadiazides, AMPA receptor allosteric potentiators, 390–392

- Biarypropylsulfonamides, AMPA receptor allosteric potentiators, 393
- Bicuculline, GABA<sub>A</sub> receptor inhibition, 468–469
- Binding affinities, GABA<sub>A</sub> subunit selectivity, 484–485
- Bioassays, neuropeptide identification, 671
- Biosynthesis
  - classical neurotransmitters, 42–43
  - histamine metabolism, 305–306
  - neuropeptides, 685–687
  - preprohormones, 686
  - prohormones, 686
  - tissue specificity, 687
- Biotin-switch method, nitrosothiol detection, 748
- Bipolar disorder
  - dopaminergic drugs, 237
  - neurobiology of
    - genetics, 860–861
    - peripheral neurochemistry, 863–864
    - postmortem findings, 861–863
    - research background, 859
    - in vivo imaging, 863
  - pharmacology
    - anticonvulsant antibipolar compounds, 869–870
    - lithium mechanism of action, 864–869
- Blood-brain barrier, neuropeptides in, 692–693
- Blood pressure, norepinephrine/epinephrine physiology and, 197–198
- Blood vessels, muscarinic acetylcholine receptor deficiency, 176
- Bovine rhodopsin, muscarinic acetylcholine receptor structure, 149–151
- Bphs* gene, H<sub>1</sub> receptor in, 307–309
- Brain-derived neurotrophic factor (BDNF)
  - AMPA receptor allosteric potentiators, 394–395
  - antidepressant treatments and expression of, 804–805
    - adult neurogenesis and, 806–808
    - 5-HT neuronal growth and, 807–808
    - stress-monoamine convergence in depression, 825–826
  - in depressed patients, 800–801
  - depression models and, 808
  - GABA<sub>A</sub> phosphorylation, 482
  - genetic studies in mood disorders, 803
  - intracellular signaling, 791–792
  - lithium mechanism in bipolar disorder and, 868–869
  - stress influence on, 794
    - adrenal glucocorticoids, 796–797
    - alterations in, 794–795
    - cytokine alterations, 797
    - neurogenesis and, 799–800
    - regulation mechanisms, 795–796
    - serotonin receptors, 797
- Brain development
  - in bipolar disorder patients, 860–861
  - GABA<sub>A</sub> receptor subunit distribution and, 471–473
  - GABA transporters and, 467–468
  - hippocampal neurogenesis and depression and, 826–827
  - voltage-gated sodium ion channels, 640–641
- Brain imaging studies, depressed patients, 802
- Brain neurotransmitters, histamine
  - biosynthesis, 305–306
  - early history, 300–301
  - inactivation, 306–307
  - metabolism, 305–307
  - molecular pharmacology, receptor subtypes, 307–317
    - H<sub>1</sub> receptor, 307–312
    - H<sub>2</sub> receptor, 312–314
    - H<sub>3</sub> receptor, 314–316
    - H<sub>4</sub> receptor, 316
    - NMDA receptor interaction, 316–317
  - neuron activity and control, 317–322
    - electrophysiology, 317
    - pharmacological changes, 321–322
    - in vitro modulation, 317–319
    - in vivo changes, 319–321
  - neuronal organization, 301–305
    - afferents, 303–305
    - histaminergic pathways, 303
    - perikarya, 301–303
  - neuron physiology, 322–326
    - arousal, 322–324
    - cognitive functions, 324
    - nociception, 326
    - pituitary hormone secretion, 324–325
    - satiating, 325–326
    - seizures, 326
  - neuropsychiatric disease, 327–329
    - Alzheimer's disease, 327–328
    - anxiety/ADHD, 329

- Parkinson's disease, 328
- schizophrenia and antipsychotic actions, 327
- Bretazenil, GABA<sub>A</sub> subunit pharmacology,
  - allosteric ligand modulation, 504–506
- Brugada syndrome, voltage-gated sodium ion channels and, 642
- $\alpha$ -Bungarotoxin, nicotinic acetylcholine receptor and, 28
- $\gamma$ -Butyrolactones, GABA<sub>A</sub> receptor modulation, 519–520
- Calcium-activated potassium channels,
  - structure and function, 630–632
- Calcium-calmodulin-dependent protein kinase II
  - amino acid neurotransmitters, 43–44
  - GABA transporters, 467–468
- Calcium channels
  - amino acid neurotransmitters, 43–44
  - in bipolar disorder patients, 862
  - calmodulin mediator, 85–87
  - cyclic nucleotide second messenger signaling, adenylyl cyclase, 72–77
  - GABA<sub>B</sub> receptors, effector systems, 581–582
  - histaminergic neuron activity, 317–319
  - H<sub>1</sub> receptor signaling, 309
  - muscarinic acetylcholine receptor modulation, 161
  - signaling molecules, 83–85
  - voltage-gated ion channels, 643–650
    - $\alpha$  subunits, 644–645
    - $\alpha\delta$  subunits, 646
    - auxiliary subunit modulators, 650
    - $\beta$  subunits, 645–646
    - Ca<sub>v</sub>1 family, 647–648
    - Ca<sub>v</sub>2 family, 648–649
    - Ca<sub>v</sub>3 family, 649–650
    - $\gamma$  subunits, 646
    - general blockers, 647
    - genetics, 619–620
    - miscellaneous channels, 650–651
- Calcium metabolism, 30–31
- Calmodulin
  - calcium channel modulation, 85–87
    - Ca<sub>v</sub>1 family, 647–648
  - intermediate-conductance
    - calcium-activated potassium channels, 631
- CamKII, GABA<sub>A</sub> receptor
  - phosphorylation, 481–482
- cAMP response element binding (CREB) protein
  - amino acid neurotransmitters, 44
  - BDNF regulation and, 805
  - calcium channel modulation, Ca<sub>v</sub>1 family, 647–648
  - lithium mechanism in bipolar disorder and, 868–869
- CA1 pyramidal cells, GABA<sub>A</sub> receptor
  - distribution on, 474–475
- CA3 pyramidal neurons, stress and, 800
- Carbon monoxide, as signaling molecule, 756–757
- 2-(Carboxycyclopropyl)glycines (CCGs),
  - mGlu II selective orthosteric agonists, 426
- S4-Carboxy phenylglycine (*S*-4CPG), mGlu
  - group I selective orthosteric antagonists, 424–425
- Cardiovascular system. *See also*
  - Arrhythmias
    - $\beta$ -adrenergic receptor physiology, 211–212
    - $\alpha_2$ -adrenergic receptor physiology, 208–209
  - KCNQ channel action on, 632–633
  - muscarinic acetylcholine receptor deficiency, 175–176
  - voltage-gated calcium channels, 647–648
  - voltage-gated sodium ion channels, 640–641
- Carrier-mediated mechanisms, blood-brain barrier neuropeptides and, 692–693
- Catalepsy, muscarinic acetylcholine receptor deficiency, 172
- Catecholamines, early research on, 30–31
- Catechol-*O*-methyltransferase (COMT)
  - dopamine synthesis, 224
  - norepinephrine neurochemistry, 198–199
- Cation channels, muscarinic acetylcholine receptor modulation, 161
- CDPPB, mGlu5 allosteric potentiators, 442–443
- Cell survival, nitrosylation and, 752
- Cellular pathways, nitrosylation in
  - cell survival, 752
  - extracellular matrix, 751–752
  - gene transcription, 750–751
  - ion channels, 748–749
  - protein-protein interactions, 749–750
  - vesicular transport, 751

- Central nervous system (CNS)  
 $\beta$ -adrenergic receptor physiology, 211–212  
 adrenergic transmitters in, 29–30  
 AMPA receptors, 370–371  
 GABA<sub>A</sub> receptor subunit distribution in, 471–473  
 5-HT<sub>7</sub> receptor family in, 275–276  
 5-HT<sub>4</sub> receptor family in, 274  
 5-HT<sub>3</sub> receptors and, 273  
 kainate receptors, 372  
 NMDA receptors, 369–370  
 serotonin impact on, 258–259  
 voltage-gated calcium ion channels, Ca<sub>v</sub>2 family, 648–649  
 voltage-gated sodium ion channels, 640–641
- Cerebrospinal fluid (CSF), blood-brain barrier neuropeptides and, 692–693
- Cesium, voltage-gated potassium channels, K<sub>V</sub> subunits, structure and function, 630
- Channel blockers  
 GABA receptor binding sites, 518–519  
 NMDA receptor allosteric antagonists, 387–389  
 voltage-gated calcium ion channels, Ca<sub>v</sub>2 family, 649
- Channel-gating process, GABA<sub>A</sub> receptor activation, 492–494  
 binding transduction to, 495–497
- Channelopathies, voltage-gated sodium ion channels, 641–642
- Channel pore structures, GABA<sub>A</sub> receptor activation, 497–498
- Charybdotoxin, intermediate-conductance calcium-activated potassium channels, 631
- Chemical neurotransmitters, categories of, 40–41
- Chimeric receptors, GABA<sub>A</sub> receptor modulation, allosteric structural determinants, 508–509
- Chlordiazepoxide (CDPX), GABA<sub>A</sub> receptor modulation, 499–500
- Chloride channels  
 early research on, 29  
 GABA receptors and, 468–469  
 muscarinic acetylcholine receptor modulation, 161–162  
 voltage-gated channels, 649–650
- (R,S)-2-Chloro-5-hydroxyphenylglycine (CHPG), mGlu group I selective orthosteric agonists, 424
- Cholecystokinin (CCK), neuropeptides and, 670–671
- Choline acetyltransferase (CHAT), structure and function, 714–715
- Choline neurotransmitter transporters (CHT), structure and function, 714–715
- Chrysin, GABA<sub>A</sub> subunit pharmacology, allosteric ligand modulation, 505–506
- Ciproxifan, histamine neuron physiology and, 324
- Circadian rhythms  
 histaminergic neuron activity, 319–322  
 reproductive cycle depression  
 future research issues, 852–853  
 neuroendocrine compounds  
 cross-reproductive cycle analysis, 851–853  
 menopause, 849–851  
 cortisol, 850  
 melatonin, 849–850  
 prolactin, 850–851  
 thyroid-stimulating hormone, 850  
 menstrual cycle, 844–846  
 cortisol, 845  
 melatonin, 844–845  
 prolactin, 846  
 thyroid-stimulating hormone, 845  
 postpartum depression, 848–849  
 cortisol, 848  
 estradiol, 849  
 melatonin, 848  
 prolactin, 848–849  
 thyroid-stimulating hormone, 848  
 pregnancy, 846–847  
 cortisol, 847  
 melatonin, 846–847  
 prolactin, 847  
 thyroid-stimulating hormone, 847  
 research background, 844
- CL-218, 872, GABA<sub>A</sub> receptor activation, benzodiazepine binding sites, 510–511
- Clathrin-mediated endocytosis, GABA<sub>A</sub> receptor trafficking, 480–481
- Clonazepam, GABA<sub>A</sub>  $\alpha_3$  subunit pharmacology, 488

- Cloning experiments  
 cyclic nucleotide second messenger signaling, adenylyl cyclase, 74–75  
 GABA<sub>B</sub> receptors, 571–572  
 glutamate receptors, 397–398  
 NMDA receptors, 369–370  
 voltage-gated ion channels, 619–620  
*Clostridium botulinum*, synaptic vesicle action and, 27  
 Clotrimazole, intermediate-conductance calcium-activated potassium channels, 631  
 Clozapine, vesicular transporters and, 723  
 Clustering behavior, GABA<sub>A</sub> receptors, 478–480  
 Cocaine- and amphetamine-regulated transcript (CART), stress response and, 695  
 Cognitive functions  
 GABA<sub>A</sub>  $\alpha_5$  subunit pharmacology, 489  
 GABA<sub>A</sub> subunit pharmacology, allosteric ligand modulation, 505–506  
 GABA<sub>B</sub> receptor targeting, 592–593  
 histamine neuron physiology, 324  
 Colorimetry, nitrosothiol detection, 748  
 Complexins, in bipolar disorder patients, 861–862  
 Concanavlin A, kainate receptor allosteric potentiators, 396  
 Congenital stationary night blindness (CSNB2), voltage-gated calcium channels, Ca<sub>v</sub>1 family, 648  
 Conotoxins  
 nicotinic acetylcholine receptors, 124  
 voltage-gated calcium ion channels, Ca<sub>v</sub>2 family, 649  
 COPI components, GABA<sub>B</sub> receptor trafficking and heteromization, 576–578  
 Corticotropin-releasing hormone (CRH), stress response and, 694–695  
 Cortisol, depression and levels of  
 in menopause, 850  
 during menstrual cycle, 845  
 postpartum depression, 848  
 in pregnancy, 846–847  
 CPCCOEt, mGlu1 allosteric antagonists, 436–437  
 CPPHA, mGlu5 allosteric potentiators, 442  
 Curare  
 action of, 4–5  
 Bernard's research on, 4–7  
 CX546, AMPA receptor allosteric potentiators, 390–391  
 CX614, AMPA receptor allosteric potentiators, 393–395  
 Cycle regulation, G proteins, 64–65  
 Cyclic adenosine monophosphate (cAMP)  
 $\alpha_1$  adrenergic receptors, 203  
 in bipolar disorder patients, 861–862  
 cyclic nucleotide second messenger signaling, 75, 78  
 second messengers and, 32  
 Cyclic guanosine monophosphate (cGMP)  
 cyclic nucleotide second messenger signaling, cellular targets, 80–81  
 GABA<sub>A</sub> phosphorylation, 481–482  
 nitric oxide physiology, 745  
 Cyclic nucleotide-gated (CNG) channels, structure and function, 649–650  
 Cyclic nucleotide second messengers, intracellular signaling, 72–81  
 adenylyl cyclase, 72–77  
 cAMP targets, 75, 78  
 cGMP targets, 80–81  
 guanylyl cyclase, 78–80  
 Cyclopropylglutamate (CCG), NMDA orthosteric agonists, 373  
 (*R,S*)- $\alpha$ -Cyclopropyl-4-phosphonophenylglycine (CPPG), mGlu III selective orthosteric agonists, 435  
 Cyclothiazide, AMPA receptor allosteric potentiators, 390–395  
 cyPPTS, mGlu2 allosteric potentiators, 438–439  
 Cys loop ligand-gated ion channel superfamily  
 GABA<sub>A</sub> receptor activation, 493–494  
 channel pore complex, 497–498  
 GABA receptors and, 468–469  
 Cysteine residues, nitric oxide nitrosylation, 747  
 Cystinyl leukotriene, mGlu2 allosteric potentiators, 439  
 Cytisine, nicotinic acetylcholine receptors, 120  
 Cytochemical assay, neuropeptide identification, 673  
 Cytokines  
 neuropeptide receptors, 691  
 stress response and, neurotrophins and, 797

- Cytolytic T cells, muscarinic acetylcholine receptor deficiency, 177
- Cytoplasmic proteins  
sodium voltage-gated ion channels, 636  
voltage-gated potassium channels, 627–628
- Cytoskeletal proteins, voltage-gated potassium channels, 628
- DAG activation, protein kinase C, 85
- D-2-amino-5-phosphonopentonoate (D-AP5), NMDA orthosteric antagonists, 373–375
- DARPP-32, protein phosphatases integration, 95–96
- Deactivation, GABA<sub>A</sub> receptors, 498–499
- Deafness, KCNQ channels and, 632–633
- Decahydroisoquinolines  
AMPA receptor orthosteric antagonists, 377–378  
kainate receptor orthosteric antagonists, 383–385
- Decarboxylation, dopamine synthesis, 54–55
- Degradation reactions, serotonin, 261–262
- Dendrotoxins, voltage-gated potassium channels, K<sub>V</sub> subunits, structure and function, 630
- Depolarization responses  
GABA receptors, 468–469  
voltage-gated calcium channels, 647–648  
voltage-gated sodium ion channels, 640
- Depression  
hippocampal neurogenesis and treatment for  
adult neurogenesis stages, 827–828  
behavioral and animal models, 833  
depression physiology and, 823–824, 826–827  
future research on, 833  
monoamines and, 822–823  
research background, 821–822  
serotonin/norepinephrine regulation, 831–833  
stress and monoamine hypotheses, 825–826  
stress hormone neurogenesis regulation, 829–830  
neurotrophic factors in, 800–802  
antidepressant therapies  
BDNR expression and, 804–806  
neurogenesis and, 806–808  
BDNF levels, 800–801
- Brain-derived neurotrophic factor and models of, 808  
fibroblast growth factor levels, 802  
structural and cellular alterations, 802–803  
in reproductive cycle, circadian studies of neuroendocrine compounds  
cross-reproductive cycle analysis, 851–853  
future research issues, 852–853  
menopause, 849–851  
cortisol, 850  
melatonin, 849–850  
prolactin, 850–851  
thyroid-stimulating hormone, 850  
menstrual cycle, 844–846  
cortisol, 845  
melatonin, 844–845  
prolactin, 846  
thyroid-stimulating hormone, 845  
postpartum depression, 848–849  
cortisol, 848  
estradiol, 849  
melatonin, 848  
prolactin, 848–849  
thyroid-stimulating hormone, 848  
pregnancy, 846–847  
cortisol, 847  
melatonin, 846–847  
prolactin, 847  
thyroid-stimulating hormone, 847  
research background, 844  
serotonin transporters and, 720
- Desensitization  
 $\alpha_1$  adrenergic receptors, 202–203  
 $\beta$ -adrenergic receptor activation, 210  
AMPA receptor allosteric potentiators, 393–395  
GABA<sub>A</sub> receptors, 498–499  
GABA<sub>B</sub> receptors, 584–585  
neuropeptide receptors, 688–689  
of nicotinic acetylcholine receptor, 125–127
- Diabetes mellitus,  $\beta$ -adrenergic receptor physiology, 212–213
- Diazepam  
GABA<sub>A</sub>  $\alpha_1$  subunit pharmacology, 484–485, 488  
GABA<sub>A</sub> receptor modulation, 499  
 $\gamma$  subunit isoforms, 509–511

- 2',3'-Dicarboxycyclopropylglycine analog (DCG-IV), mGlu II selective orthosteric agonists, 426–427
- 3,3'-Difluorobenzaldazine, mGlu5 allosteric potentiators, 441–442
- Dihydroxyphenylalanine (DOPA), norepinephrine/epinephrine neurochemistry, 198–199
- 3,5-Dihydroxyphenylglycine (3,5-DHPG), mGlu group I selective orthosteric agonists, 423–424
- Diisopropyl fluorophosphate (DFP), synapse research and, 23
- Dimerization  
 $\alpha_1$  adrenergic receptors, 201–203  
 muscarinic acetylcholine receptors, 166–167
- Dipeptidyl-peptidase IV (DPP IV), neuropeptide inactivation, 687–688
- Disease, G proteins and, 66
- DMPP agonist, nicotinic acetylcholine receptors, 120
- DOPA (3,4-dihydroxyphenylalanine), early research on, 30–31
- Dopamine  
 histaminergic neuron activity, Parkinson's disease, 328  
 $H_3$  receptor synthesis, 315–316  
 muscarinic acetylcholine receptor deficiency  
 efflux nucleus accumbens, 172–173  
 striatal release, 171–172  
 neurotransmission  
 attention-deficit hyperactivity disorder, 237–238  
 basic properties, 221–222  
 bipolar disorders, 237  
 chemistry and metabolism, 222–224  
 classification and molecular properties, 225–230  
 $D_1$  receptor subfamily, 225–227  
 $D_2$  receptor subfamily, 227–230  
 drug applications, 236–239  
 mechanisms, 54–55  
 Parkinson's disease, 236  
 polymorphisms, splice variants and SNPs, 234–236  
 schizophrenia, 237  
 signal transduction pathways, 230–232  
 structure-affinity/structure-activity relationships, 232–234  
 substance abuse, 238  
 transporters  
 chronic substrate treatment, 726  
 clinical relevance, 721  
 multiple interactions, 723–724  
 polymorphisms, 724–725  
 structure and function, 712–713
- Downregulation  
 muscarinic acetylcholine receptors, 163–164  
 neuropeptide receptors, 688–689
- Downstream signaling molecules, ion channel modulation, 69–70
- $D_1$  receptor, subfamily, 225–227
- $D_2$  receptor, subfamily, 227–230
- $D_3$  receptor subunit, properties of, 229–230
- $D_4$  receptor subunit, properties of, 230
- Drug abuse. *See* Substance abuse
- Drug interactions  
 $\alpha_1$  adrenergic receptors, 202–203  
 dopaminergic drugs, 236–239  
 attention-deficit hyperactivity disorder, 237–238  
 bipolar disorders, 237  
 Parkinson's disease, 236  
 schizophrenia, 237  
 muscarinic acetylcholine receptors, 154
- Dysiherbaine, kainate receptor orthosteric agonists, 380
- EAG genes, KCNH potassium channels, 633–634
- Effector systems, GABA<sub>B</sub> receptors, 580–583  
 adenylate cyclase, 582–583  
 calcium channels, 581–582  
 G-protein-dependent/independent GABA<sub>B</sub> effects, 580–581
- MAPKs, 583  
 potassium channels, 582
- Electrophysiology  
 histaminergic neuron activity, 317  
 neuropeptides, 675–677  
 neurohormones, 675–676  
 neuromodulators, 676–677  
 neurotransmitters, 676  
 potassium channels, 625
- Electrospray ionization mass spectrometry (ESI-MS), nitrosothiol detection, 747–748
- ELK genes, KCNH potassium channels, 633–634
- Endocannabinoids

- packaging of, 46
- synthesis of, 45
- Endocytosis, neuropeptide receptor
  - downregulation, 688–689
- Endothelium-derived relaxing factor (EDRF), nitric oxide and, 743–745
- End-plate potentials, early research on, 26–27
- Enzymes, neurotransmitter biosynthesis, 42–43
- Epibatidine, nicotinic acetylcholine receptors, 121
- Epileptic seizures
  - GABA<sub>A</sub>  $\beta$  subunit pharmacology, 490–491
  - GABA<sub>B</sub> receptor therapy, 595
  - histamine neuron physiology, 326
  - muscarinic acetylcholine receptor deficiency, 169
  - NMDA orthosteric antagonists, 375–377
  - voltage-gated sodium ion channels and, 642
- Epinephrine
  - $\alpha$ -adrenergic receptors,  $\alpha_2$ -adrenergic receptor, 205–206
  - $\beta$ -adrenergic receptor activation, 209–210
  - basic properties, 193
  - dopamine synthesis, 223–224
  - historical perspective, 194–196
  - neurochemistry, 198–199
  - physiology, 197–198
- Episodic ataxia type 1 (EA-1), voltage-gated potassium channels, K<sub>V</sub> subunits, structure and function, 629–630
- Ergot, early research on, 15–16
- Estradiol, postpartum depression and levels of, 849
- Estrogen receptors, histaminergic neuron activity, 325
- Ethanol
  - GABA<sub>A</sub> receptor modulation, 516
  - histaminergic neuron activity, 321–322
- Evolutionary relationships
  - neuropeptides, 679–685
    - gene duplication, 680–685
    - gene splicing, 685
    - neurohypophyseal family, 682–684
    - NPY family, 684
    - opioid family, 680–682
    - structural conservation, 679–680
    - voltage-gated ion channels, 619–620
- Excitatory amino acid transporter (EAAT)
  - glutamate neurotransmitters, 53–54
  - plasma membrane glutamate transporter, clinical relevance, 718–719
  - plasma membrane glutamate transporters, 708–711
- Excitatory postsynaptic potentials (EPSPs)
  - early research on, 28–29
  - mGlu2 allosteric potentiators, 438–439
  - neuropeptides and, 676–677
- Excitatory responses
  - H<sub>2</sub> receptor, 312–313
  - H<sub>1</sub> receptor signaling, 309–311
- Exocrine pancreas, amylase secretion, muscarinic acetylcholine receptor deficiency, 175
- Exocytosis, neuropeptide electrophysiology, 676
- Extracellular calcium, GABA<sub>B</sub> receptor modulation, 584
- Extracellular catabolism, dopamine synthesis, 55
- Extracellular domain (ECD), GABA<sub>B</sub> receptors
  - modulation, 585–587
  - sites, 578–579
  - subtypes, 573–575
- Extracellular inactivation, neuropeptides, 687–688
- Extracellular matrix (ECM), nitrosylation and, 751–752
- Extracellular signal-related kinase (ERK)
  - brain-derived neurotrophic factor in depressed patients and, 801
  - GABA<sub>B</sub> receptors, effector systems, 583
  - lithium mechanism in bipolar disorder patients, 867–869
  - muscarinic acetylcholine receptor modulation, 159
  - phosphorylation, 89–90
- "Fail-safe" mechanism, stress response and, 695
- Famotidine, histaminergic neuron activity, 327
- Fast inactivation, potassium channels, 627
- Fatty acids, GABA<sub>A</sub> receptor modulation, 520
- Fibroblast growth factor (FGF)
  - antidepressant influences on, 805–806
  - in depressed patients, 802
  - intracellular signaling, 793

- Filamin, voltage-gated potassium channels, 628
- FKBP5 cochaperone, stress-monoamine convergence in depression, 825–826
- Flavonoids, GABA<sub>A</sub> subunit pharmacology, allosteric ligand modulation, 505–506
- Flip/flop exons  
 AMPA receptor allosteric potentiators, 393  
 AMPA receptors, 370–371
- Flumazenil, GABA<sub>A</sub>  $\alpha_6$  subunit pharmacology, 489–490
- Fluorometry, nitrosothiol detection, 748
- Follicle-stimulating hormone, in menopause, 851
- Food intake stimulation  
 histaminergic neuron activity, 320–322  
 muscarinic acetylcholine receptor deficiency, 171
- GABAergic neurons  
 histaminergic neuron activity, 319–322  
 H<sub>2</sub> receptor, 313
- Gabapentin, voltage-gated calcium ion channels, auxiliary subunit modulators, 650
- GABARAP polypeptide, GABA<sub>A</sub> receptor trafficking, 478–480
- GABA transporters (GATs), structure and function, 711–712
- GAD protein, in bipolar disorder patients, 862
- Galanin, histaminergic neuron activity, 318–319
- $\gamma$ -amino butyric acid (GABA) receptors  
 A, B, and C receptor classifications, 468–469  
 adult neurogenesis and, 829  
 agonist binding site architecture, 494–495  
 binding-to-gating transduction, 495–497  
 in bipolar disorder patients, 861–862  
 channel blocker binding sites, 518–519  
 channel pore ion selectivity, 497–498  
 early research on, 32, 466  
 GABA<sub>A</sub> receptors  
 allosteric modulation  
 benzodiazepine recognition site, 499–506  
 structural determinants, 507–509  
 $\alpha$  subunit pharmacology, 483–490, 509–511  
 $\alpha_1$  subunit, 484, 488  
 $\alpha_2$  subunit, 488  
 $\alpha_3$  subunit, 488  
 $\alpha_4$  subunit, 488–489  
 $\alpha_5$  subunit, 489  
 $\alpha_6$  subunit, 489–490  
 electrophysiology, 486–487  
 modulator selectivity, 484  
 terminology, 483  
 assembly, 477–478  
 benzodiazepine binding site, 506–507  
 subunit isoforms, 509–511  
 $\beta$  subunit pharmacology, 490–491  
 $\delta$  subunit pharmacology, 491–492  
 desensitization and deactivation, 498–499  
 $\epsilon$  subunit distribution, 472, 492  
 $\gamma$  subunit pharmacology, 491–492, 509–511  
 hetero-oligomeric structure, 476–477  
 homo-oligomeric structure, 476  
 modulation mechanisms, 511–516  
 pharmacology, 482–483  
 phosphorylation, 481–482  
 $\pi$  subunit distribution, 472, 492  
 rare subunits, 492  
 $\rho$  subunit distribution, 472  
 structure, 475  
 subcellular distribution, 473–475  
 $\theta$  subunit distribution, 472, 492  
 trafficking, 478–481  
 transmembrane domain allosteric sites, subunits, 516–518  
 unidentified allosteric modulation, 519–520
- GABA<sub>B</sub> receptors  
 deficient mice, 587–588  
 effector systems, 580–583  
 endogenous GABA<sub>B</sub> ligands, 588–589  
 expression cloning, 571–572  
 G-protein coupling determinants, 579–580  
 ligand binding sites, 578–579  
 modulation mechanisms, 584–586  
 molecular subtypes, 572–575  
 novel compounds, 590–592  
 structure and function, 570–571  
 trafficking and heteromization, 575–578  
 histaminergic perikarya, 302–303  
 ion channel modulation, protein-protein interaction, 70–71  
 metabotropic receptors

- agonists and competitive antagonists, 589–590
- disease and, 592–597
  - anxiety and depression, 594–595
  - drug addiction, 593–594
  - epilepsy, 595
  - gene linkage studies, 596–597
  - nociception, 595–596
  - therapeutic targeting, GABA<sub>B</sub> receptors, 592–593
  - tumor cell growth and migration, 596
- effector systems, 580–583
  - adenylate cyclase, 582–583
  - calcium channels, 581–582
  - G-protein-dependent/independent GABA<sub>B</sub> effects, 580–581
  - MAPKs, 583
  - potassium channels, 582
- endogenous GABA<sub>B</sub> ligands, 588–589
- GABA<sub>B</sub> deficient mice, 587–588
- GABA<sub>B</sub> novel compounds, 590–592
- GABA<sub>B</sub> receptor modulation, 584–586
  - extracellular calcium, 584
  - interacting proteins, 585–587
  - phosphorylation and desensitization, 584–585
- research background, 570–571
- structural properties, 571–580
  - allosteric interactions, 580
  - expression cloning, 571–572
  - G-protein coupling determinants, 579–580
  - liganding binding sites, 578–579
  - molecular subtypes, 572–575
  - surface trafficking and heteromerization, 575–578
- neuropeptides and, 671
- plasma membrane neurotransmitter transporters
  - clinical relevance, 721–722
  - interacting protein regulation, 728
  - structure and function, 711–712
- structural determinants of activation, 492–494
- subunit genes, 469–470
  - central nervous system distribution, 471–473
- transmitter inactivation, 51–52
- transporters, 467–468
- Gamma glutamate analogs, kainate receptor orthosteric agonists, 378–379
- $\gamma$ -glutamyl transpeptidase, nitric oxide nitrosylation, 747
- Ganaxolone, GABA<sub>A</sub> receptor modulation, 515–516
- Gaseous signaling
  - carbon monoxide, 756–757
  - future research, 757
  - nitric oxide
    - basic principles, 743–744
    - neurodegeneration and, 754
    - nitrosothiol detection, 747–748
    - nitrosylation mechanism, 745–747
      - cell survival, 752
      - extracellular matrix, 751–752
      - gene transport, 750–751
      - ion channels, 748–749
      - Parkinson's disease and, 755–756
      - protein-protein interactions, 749–750
      - S nitrosylation physiology, 752–754
      - vesicular transport, 751
    - physiological role, 745
  - packaging of, 46
  - synthesis, 45
- Gastric acid secretion, muscarinic acetylcholine receptor deficiency, 175
- Gastrointestinal disorders, serotonin transporters and, 720
- Gating mechanisms, voltage-gated potassium channels, 626–627
- G $\beta\gamma$  signaling, to ion channels, 67–69
- Geller-Seifter conflict test, mGlu5 allosteric antagonists, 444
- Gene duplication, neuropeptides, 680–682
- Gene expression, neuropeptides, 685
- Gene splicing
  - neuropeptides, 685
  - plasma membrane transporter regulation, 725
- Gene therapy, vesicular transporters and, 723
- Genetic absence-epilepsy rats from Strasbourg (GAERS), GABA<sub>B</sub> receptors, 595
- Genetic analysis
  - $\alpha_1$  adrenergic receptors, 201–202
  - $\beta$ -adrenergic receptor physiology, 211–213
  - bipolar disorder, 860
  - GABA<sub>A</sub> receptor subunits, 469–470
  - neuropeptides, 678–679
    - knockout mice, 678
    - transgenic animals, 678

- norepinephrine transporter, 200–201
- Parkinson's disease and, 755–756
- Genetic linkage studies
  - BDNF in mood disorders, 803
  - GABA<sub>B</sub> receptor targeting, 596–597
- Gene transcription, nitrosylation and, 750–751
- Genome sequencing, potassium channels, 621–623
- Genomics, neuropeptides and, 678–679
- Gephyrin, GABA<sub>A</sub> receptor clusters, 478–480
- GHB (Xyrem), GABA<sub>B</sub> receptor targeting, 592–593
- Giant depolarizing potentials, GABA transporters, 467–468
- GLAST knockout mice, plasma membrane glutamate transporters, 711
- Glial-derived neurotrophic factor (GDNF), intracellular signaling, 793–794
- Glial proliferation
  - antidepressant influences on, 807
  - stress and, 800
- GLT1 knockout mice, plasma membrane glutamate transporters, 711
- Glucagon-like peptides, neuropeptide inactivation, 687–688
- Glucagon secretion, muscarinic acetylcholine receptor deficiency, 174–175
- Glucocorticoids
  - in bipolar disorder patients, 861–862
  - neurogenesis regulation by, 830
  - stress influence on BDNF and, 796–797
  - stress response and, 694–695
- Glucose-related protein 78 (GRP78), in bipolar disorder patients, 870
- Glutamate
  - ionotropic receptors
    - allosteric potentiators and antagonists, 385–397
  - AMPA receptors, 370–371
    - allosteric antagonists, 395–396
    - allosteric potentiators, 390–395
    - orthosteric agonists, 376–377, 378–381
    - orthosteric antagonists, 377–378, 381–385
  - classification and background, 365–366
  - future research issues, 397–398
  - kainate receptors, 371–372
    - allosteric antagonists, 397
    - allosteric potentiators, 396
  - NMDA receptors, 367–370
    - allosteric antagonists, 386–390
    - allosteric potentiators, 385–386
    - orthosteric agonists, 373
    - orthosteric antagonists, 373–376
  - orthosteric pharmacological agents, 373–385
    - subtypes, 366–367
  - synthesis and storage, 366
- metabotropic receptors
  - allosteric potentiators and antagonists
    - mGlu1 antagonists, 436–437
    - mGlu2/3 antagonists, 439–440
    - mGlu5 antagonists, 443–445
    - mGlu7 antagonists, 445
    - mGlu1 potentiators, 435–436
    - mGlu2 potentiators, 437–439
    - mGlu4 potentiators, 440–441
    - mGlu5 potentiators, 441–443
  - background and classification, 421–422
  - future research issues, 445–446
  - orthosteric agents
    - group III selective agonists, 431–433
    - group III selective antagonists, 433–435
    - group II selective agonists, 426–429
    - group II selective antagonists, 429–431
    - group I selective agonists, 423–424
    - group I selective antagonists, 424–426
  - neurotransmitter mechanisms, 53–54
  - plasma membrane neurotransmitter transporters
    - clinical relevance, 718–719
    - interacting proteins, 728
    - second messenger regulation, 727–728
    - structure and function, 708–711
  - vesicular transporters
    - clinical relevance, 723
    - structure and function, 716
- L-Glutamic acid decarboxylase (GAD), GABA catalysis, 466
- Glutamine neurotransmitter transporter, structure and function, 715
- Glutamatergic signaling, in bipolar disorder patients, 862–863
- $\gamma$ -D-Glutamylaminomethylsulfonic acid (GAMS)

- kainate receptor orthosteric antagonists, 385
- Glycine  
 binding site agonists, NMDA allosteric potentiators, 385–386  
 competitive site antagonists, NMDA receptors, 386–389  
 early research on, 32  
 neurotransmitter transporters  
 clinical relevance, 722–723  
 structure and function, 712
- Glycogen breakdown, second messengers and, 31–32
- Glycogen synthase kinase-3 (GSK-3), lithium mechanism in bipolar disorder patients, 864–869
- Glycosylation, plasma membrane transporter regulation, 725–726
- Golgi-specific DHHC zinc finger protein (GODZ), GABA<sub>A</sub> receptor trafficking, 480
- Gonadotropin-releasing hormone (GnRH), neuropeptides and, 676
- G protein  
 in bipolar disorder patients, 861–862  
 muscarinic acetylcholine receptors, selectivity, 157–158  
 signal transducers, 60–66  
 cycle regulations, 64–65  
 disease and, 67  
 heterotrimeric protein structure, 60–63  
 RGS proteins, 65–66  
 small proteins, 63–64
- G-protein-activated inwardly rectifying K<sup>+</sup> (GIRK) channel  
 signaling mechanisms, 67–69  
 structure and function, 635
- G-protein-coupled receptors (GPCRs). *See also* Adrenergic receptors  
 chemical release, 48–50  
 dopamine, 225  
 dopamine signal transducers, 230–232  
 GABA<sub>B</sub> molecular determinants, 579–580  
 GABA<sub>B</sub> receptors, dependent and independent effects, 580–581  
 glutamate neurotransmitters, 53–54  
 ion channel modulation, 66–71  
 downstream signaling molecules, 69–70  
 Gβγ signaling, 67–69  
 protein-protein interactions, 70–71  
 muscarinic acetylcholine receptors  
 basic properties, 155–157  
 downregulation, 163–164  
 internalization, 162–163  
 RGS proteins, 158  
 uncoupling, 162  
 muscarinic acetylcholine receptors and, 149–151  
 neuropeptide receptors, 689–690
- G-protein receptor kinases (GRKs)  
 α<sub>2</sub>-adrenergic receptor regulation, 205–206  
 D<sub>1</sub> receptor subfamily, 225–227  
 muscarinic acetylcholine receptor phosphorylation, 164–166  
 phosphorylation, 90–92  
 RGS protein function, 65–66
- Growth factors, intercellular signaling, 44–45, 46
- GTPase-activating proteins (GAPs), cycle regulation, 64–65
- Guanine nucleotide exchange factors (GEFs), small G proteins, 63–64
- Guanosine diphosphate (GDP)  
 dopamine signal transducers, 231–232  
 heterotrimeric G protein binding, 60–73
- Guanosine triphosphate (GTP), heterotrimeric G protein binding, 60–73
- Guanylate cyclase (cGMP) receptors  
 neuropeptides, 691  
 nitric oxide gaseous signaling, nitrosylation, 745–747
- Guanylyl cyclases (GCs), cyclic nucleotide second messenger signaling, 78–80
- Haloperidol-induced catalepsy, muscarinic acetylcholine receptor deficiency, 172
- Heart function, muscarinic acetylcholine receptor deficiency, 175
- HERG gene  
 KCNH potassium channels and, 633–634  
 voltage-gated potassium channels, 623
- 3-Heteroaryl-5,6bis(aryl)-1-methyl-2-pyridone, GABA<sub>A</sub> α<sub>3</sub> subunit pharmacology, 488
- Heteromeric structure  
 GABA<sub>B</sub> receptors, 575–578  
 nicotinic acetylcholine receptors, 112–113, 116–125
- Hetero-oligomeric receptors, GABA<sub>A</sub> receptors, subunit subtype composition, 476–477

- Heteroreceptors, muscarinic acetylcholine receptor deficiency, 176
- Heterotrimeric G proteins, structure and function, 60–63
- Hexamethonium blockers, nicotinic acetylcholine receptors, 121
- Hippocampal system  
 anatomy and physiology, 823–824  
 antidepressants and neurogenesis in  
 adult neurogenesis stages, 827–828  
 behavioral and animal models, 833  
 depression physiology and, 823–824, 826–827  
 future research on, 833  
 monoamines and, 822–823  
 research background, 821–822  
 serotonin/norepinephrine regulation, 831–833  
 stress and monoamine hypotheses, 825–826  
 stress hormone neurogenesis regulation, 829–830
- synapses  
 5-HT<sub>7</sub> receptor family, 276  
 mGlu5 allosteric potentiators, 441–442  
 muscarinic acetylcholine receptor deficiency and suppression of, 172  
 neurotrophins and, stress and neurogenesis in, 798–799  
 vesicular transporters and, 723
- Hispidulin, GABA<sub>A</sub> subunit pharmacology, allosteric ligand modulation, 506
- Histamine  
 in brain  
 biosynthesis, 305–306  
 early history, 300–301  
 inactivation, 306–307  
 metabolism, 305–307  
 molecular pharmacology, receptor subtypes, 307–317  
 H<sub>1</sub> receptor, 307–312  
 H<sub>2</sub> receptor, 312–314  
 H<sub>3</sub> receptor, 314–316  
 H<sub>4</sub> receptor, 316  
 NMDA receptor interaction, 316–317  
 neuron activity and control, 317–322  
 electrophysiology, 317  
 pharmacological changes, 321–322  
 in vitro modulation, 317–319  
 in vivo changes, 319–321  
 neuronal organization, 301–305  
 afferents, 303–305  
 histaminergic pathways, 303  
 perikarya, 301–303  
 neuron physiology, 322–326  
 arousal, 322–324  
 cognitive functions, 324  
 nociception, 326  
 pituitary hormone secretion, 324–325  
 satiation, 325–326  
 seizures, 326  
 neuropsychiatric disease, 327–329  
 Alzheimer's disease, 327–328  
 anxiety/ADHD, 329  
 Parkinson's disease, 328  
 schizophrenia and antipsychotic actions, 327  
 early research on, 16–17
- Histamine *N*-methyltransferase (HMT), histamine inactivation, 306–307
- Histaminergic pathways, structure and function, 303
- Histaminergic perikarya, structure and function, 301–303
- L-Histidine decarboxylase (HDC)  
 histamine neuron physiology, arousal mechanisms, 322–324  
 histaminergic perikarya and, 301–303
- Histochemistry, neuropeptide identification, 674
- Homologous residues, GABA<sub>A</sub> receptor activation, channel gating binding, 497
- Homooligomeric receptors, GABA<sub>A</sub> receptors, 476
- H<sub>1</sub> receptor  
 arousal mechanisms, 323–324  
 molecular pharmacology, 307–312  
 brain tissue responses, 309–311  
 distribution, 311–312  
 signaling mechanisms, 309  
 structure and properties, 307–309
- H<sub>2</sub> receptor, molecular pharmacology, 312–314
- H<sub>3</sub> receptor  
 cognitive functions, 324  
 histaminergic neuron activity, 321–322  
 molecular pharmacology, 314–316
- H<sub>4</sub> receptor, molecular pharmacology, 316
- 5-HT<sub>7</sub> receptor family, structure and function, 275–276

- 5-HT<sub>1</sub> receptor family. *See also* Serotonin systems  
 classification, 263–264  
 5-HT<sub>1A</sub> receptors, 263, 266–267  
 5-HT<sub>1B</sub> and 5-HT<sub>1D</sub> receptors, 267–268  
 5-HT<sub>1E</sub> receptors, 268–269  
 5-HT<sub>1F</sub> receptors, 269  
 5-HT<sub>2</sub> receptor family, 269–273  
 5-HT<sub>2A</sub> receptors, 270–271  
 5-HT<sub>2B</sub> receptors, 271  
 5-HT<sub>2C</sub> receptors, 271–272  
 5-HT<sub>3</sub> receptor family, structure and function, 273  
 5-HT<sub>4</sub> receptor family, structure and function, 273–274  
 5-HT<sub>5</sub> receptor family, structure and function, 274–275  
 5-HT<sub>6</sub> receptor family, structure and function, 275  
 Huntington's disease, H<sub>1</sub> receptor distribution, 313–314  
 7-Hydroxyiminocyclopropan[*b*]chromene-1 $\alpha$ -carboxylic acid, mGlu1 allosteric antagonists, 436–437  
 Hydroxylation, dopamine synthesis, 54–55  
 5-Hydroxytryptamine (5-HT). *See also* 5-HT<sub>1</sub> receptor family; Serotonin systems  
 Hyperkalemic periodic paralysis (HyperPP), voltage-gated sodium ion channels and, 641–642  
 Hyperpolarization-activated channels (HCN), structure and function, 649–650  
 Hypertension therapy, voltage-gated calcium channels, Ca<sub>v</sub>1 family, 648  
 Hypothalamic-pituitary-adrenal (HPA) axis  
 hippocampal neurogenesis and depression and, 827  
 stress response and, 694–695  
 Hypothalamic-pituitary pathways, neuropeptides, 692  
 Hypothalamic release-stimulating/release-inhibiting actions, neuropeptides, 691  
 Hypothalamus  
 histamine neuron physiology  
 arousal mechanisms, 323–324  
 satiation effects, 325–326  
 neuropeptide control, 691–692  
 Hypothermia, muscarinic acetylcholine receptor deficiency, 170–171  
 Hypoxia, S nitrosylation physiology and, 753–754  
 Ifenprodil, NMDA receptor allosteric antagonists, 390  
 Imidazenil, GABA<sub>A</sub> subunit pharmacology, allosteric ligand modulation, 504–506  
 Iminodibenzyl derivatives, early research on, 30  
 Imipramine, early research on, 30–31  
 Immediate early genes, neuropeptide identification, 673  
 Immunocytochemistry, neuropeptide identification, 673  
 Immunosuppression, intermediate-conductance calcium-activated potassium channels, 631  
 Inactivation  
 histamines, 306–307  
 neuropeptides, 687–688  
 extracellular inactivation, 687–688  
 neurotransmitters, 50–52  
 of nicotinic acetylcholine receptor, 125–127  
 potassium ion channels, 627  
 Inhibitory postsynaptic potential (IPSP)  
 early research on, 29  
 neuropeptides and, 676–677  
*INO1* gene, lithium mechanism in bipolar disorder and, 869  
 Inositol depletion, lithium mechanism in bipolar disorder and, 869  
 In situ hybridization, neuropeptide identification, 674  
 Insulin-like growth factor (IGF-1)  
 depression models and, 809  
 intracellular signaling, 763  
 Insulin secretion  
 $\beta$ -adrenergic receptor physiology, 212–213  
 GABA<sub>A</sub> receptor trafficking, 480  
 muscarinic acetylcholine receptor deficiency, 174–175  
 neurotrophic factors and, 763  
 Interacting proteins  
 GABA<sub>B</sub> receptor modulation, 585–587  
 G-protein-coupled receptors, 70–71

- plasma membrane transporter regulation, 728
- voltage-gated potassium channels, 627–628
- Intercellular signaling, synaptic transmission
  - basic principles, 40–41
  - classical transmitters, 45–46
  - dopamine neurotransmitters, 54–56
  - endocannabinoids, purines, and gaseous transmitters, 46
  - glutamate neurotransmitters, 52–54
  - peptide transmitters and growth factors, 46
  - postsynaptic receptors, 48–50
  - presynaptic receptors, 50–51
  - synaptic release, 46–48
  - transmitter inactivation, 51–52
  - transmitter packaging, 45–46
  - transmitter synthesis, 41–45
    - amine transmitters, 42–44
    - endocannabinoids, 45
    - gaseous transmitters, 45
    - neuropeptides, neurotrophins, and growth factors, 44–45
  - vesicle-dependent release, 46–47
  - vesicle-independent release, 47–48
- Interleukin-1 $\beta$  (IL- $\beta$ ), stress response and, 797
- Intermediate-conductance calcium-activated potassium channels (IK channels), structure and function, 631
- Internalization, muscarinic acetylcholine receptors, 162–163
- Intracellular signaling
  - GABA<sub>B</sub> receptor modulation, 585–586
  - neuropeptide degradation, 687
  - neurotrophic factors, 791–794
    - fibroblast growth factor, 793
    - insulin/insulin-like growth factor, 793
    - nerve growth factor family, 791–792
    - transforming growth factor-beta, 793–794
  - vascular endothelial growth factor, 792–793
- synaptic transmission
  - basic principles, 59–60
  - calcium channel calmodulin mediator, 85–87
  - calcium channel signaling molecules, 83–85
  - cyclic nucleotide second messengers, 72–81
    - adenylyl cyclase, 72–77
    - cAMP targets, 75, 78
    - cGMP cellular targets, 80–81
    - guanylyl cyclase, 78–80
  - DAG activation of protein kinase C, 85
  - GPCR-G protein ion channel
    - modulation, 66–71
    - downstream signaling molecules, 69–70
    - G $\beta\gamma$  signaling, 67–69
    - protein-protein interactions, 70–71
  - G protein signal transducers, 60–66
    - cycle regulations, 64–65
    - disease and, 67
    - heterotrimeric protein structure, 60–63
    - RGS proteins, 65–66
    - small proteins, 63–64
  - IP<sub>3</sub> and phosphoinositide signaling molecules, 81–83
  - protein phosphorylation, 87–96
    - G-protein-coupled receptor kinases, 90–92
    - mitogen-activated protein kinase, 89–90
    - protein tyrosine kinase, 87–89
    - protein tyrosines phosphatases, 92–94
    - serine/threonine phosphatases, 94–96
- Introns, H<sub>3</sub> receptor, 314–315
- Inverse agonism, GABA<sub>A</sub> receptor
  - activation, allosteric ligand
  - modulation, 500–506
- In vitro modulation, histaminergic neuron activity, 317–319
- In vivo modulation
  - in bipolar disorder patients, 863
  - GABA<sub>B</sub> deficient mice, 587–588
  - histaminergic neuron activity, 319–322
- Inwardly rectifying potassium, structure and function, 634–635
- Ion channels
  - early research on, 25
  - GABA<sub>A</sub> receptor activation, channel pore complex, 497–498
  - GABA<sub>B</sub> receptor and, 469
  - G-protein-coupled receptor modulation, 66–71
    - downstream signaling molecules, 69–70
    - G $\beta\gamma$  signaling, 67–69
    - protein-protein interactions, 70–71
  - muscarinic acetylcholine receptor
    - modulation, 160–162
  - nitrosylation in, 748–759

- Ionotropic channels  
 chemical release, 48–50  
 glutamate receptors  
 allosteric potentiators and antagonists, 385–397  
 AMPA receptors, 370–371  
 allosteric antagonists, 395–396  
 allosteric potentiators, 390–395  
 orthosteric agonists, 376–377, 378–381  
 orthosteric antagonists, 377–378, 381–385  
 classification and background, 365–366  
 future research issues, 397–398  
 kainate receptors, 371–372  
 allosteric antagonists, 397  
 allosteric potentiators, 396  
 NMDA receptors, 367–370  
 allosteric antagonists, 386–390  
 allosteric potentiators, 385–386  
 orthosteric agonists, 373  
 orthosteric antagonists, 373–376  
 orthosteric pharmacological agents, 373–385  
 subtypes, 366–367  
 synthesis and storage, 366  
 IP<sub>3</sub> signaling molecules, intracellular signaling, 81–83  
 Ischemia. *See* Stroke therapy  
 Isoquinolin-pyrimidines, NMDA receptor allosteric antagonists, 390  
 Iso receptors, neuropeptides, 689  
 JC virus, 5-HT<sub>2A</sub> receptors and, 271  
 Jervall-Lange-Nielsen syndrome, KCNQ channels and, 632–633  
 K36, GABA<sub>A</sub> subunit pharmacology, allosteric ligand modulation, 505–506  
 Kainate receptors  
 allosteric antagonists, 397  
 allosteric potentiators, 396  
 orthosteric agonists, 378–381  
 orthosteric antagonists, 381–385  
 structure and function, 371–372  
 K<sup>+</sup> channel interacting protein (KChIPs), voltage-gated potassium channels, 628  
 KCNE proteins, voltage-gated potassium channels, 628  
 KCNH potassium channels  
 clinical conditions and, 633–634  
 structure and function, 623  
 KCNQ channels  
 clinical applications, 632–633  
 structure and function, 623  
 KcsA channel, gating mechanism, 626–627  
 Ketamine  
 NMDA receptor allosteric antagonists, 389–390  
 NMDA receptors, 368–370  
 Knockout (KO) mice  
 GABA<sub>A</sub> subunit pharmacology,  $\alpha$  subunits,  $\alpha_1$  subunit, 484, 488  
 GABA<sub>B</sub> deficient mice, 587–588  
 neuropeptide gene targeting in, 678  
 plasma membrane glutamate transporters, 711  
 Kymarenic acid, kainate receptor orthosteric antagonists, 385  
 Kynuremic acid, NMDA receptor allosteric antagonists, 387  
 L-655,708, GABA<sub>A</sub>  $\alpha_5$  subunit pharmacology, 489  
 L-838,417, GABA<sub>A</sub> subunit pharmacology, allosteric ligand modulation, 505–506  
 Large-conductance calcium-activated potassium channels (BK channels), structure and function, 630–631  
 Large dense-core vesicles (LDCVs), neuropeptide electrophysiology, 675–676  
 Learning function, muscarinic acetylcholine receptor deficiency, 168–169  
 Leucine binding protein (LBP), GABA<sub>B</sub> receptor sites, 578–579  
 Leucine residues, GABA<sub>A</sub> receptor activation, channel pore complex, 497–498  
 Leukotriene D4 (LTDR), mGlu2 allosteric potentiators, 439  
 Ligand binding core (LBC)  
 AMPA receptor allosteric potentiators, 393–395  
 AMPA receptor orthosteric agonists, 377  
 AMPA receptors, 370–371  
 Ligand binding domain (LBD)  
 dopamine, 233–234  
 GABA<sub>A</sub> receptors

- agonist binding site architecture, 494–495
- allosteric ligand modulation, 499–506 assembly, 477–478
- GABA<sub>B</sub> receptor sites, 578–579
- muscarinic acetylcholine receptors (mAChRs), 152–154
  - agonists, 152
  - allosteric ligands, 153–154
  - antagonists, 152–153
  - clinical applications, 154
  - serotonin receptor families, 263–267
- Ligand-gated ion channels
  - GABA<sub>A</sub> receptors, desensitization and deactivation, 498–499
  - glutamate neurotransmitters, 53–54
  - 5-HT<sub>3</sub> receptor family and, 273
- Lithium, mechanism in bipolar disorder patients, 864–869
- Lobeline, vesicular transporters and, 723
- Localization studies
  - H<sub>2</sub> receptor, 313–314
  - H<sub>1</sub> receptor distribution, 311–312
  - H<sub>3</sub> receptors, 316
- Locomotor activity
  - GABA<sub>A</sub>  $\alpha_6$  subunit pharmacology, 489–490
  - mGlu5 allosteric potentiators, 442–443
  - mGlu II selective orthosteric antagonists, 431
  - muscarinic acetylcholine receptor deficiency, 169–170
- Long-QT syndrome
  - KCNQ channels and, 632–633
  - voltage-gated sodium ion channels and, 642
- Long-term potentiation (LTP), adult neurogenesis and, 829
- L*-4-phosphono-2-aminobutyric acid (*L*-AP4), mGlu III selective orthosteric agonists, 433–435
- Luteinizing hormone releasing hormone (LHRH), histaminergic neuron activity, 325
- LY34195, mGlu II selective orthosteric antagonists, 430–431
- LY354740, mGlu II selective orthosteric agonists, 426–428
- LY367385, mGlu I selective orthosteric antagonists, 425–426
- LY392098, AMPA receptor allosteric potentiators, 390–391
- LY487379, mGlu2 allosteric potentiators, 437–439
- LY520303, mGlu II selective orthosteric agonists, 426–427
- LY4464333, mGlu II selective orthosteric agonists, 426–427
- LY379268/LY389795, mGlu II selective orthosteric agonists, 428–429
- Magnesium ions
  - NMDA receptor allosteric antagonists, 387–389
  - second messengers and, 31–32
- Magnocellular system,
  - hypothalamic-pituitary pathways, 692
- Major depressive disorder (MDD). *See* Depression
- Marine products, kainate receptor orthosteric agonists, 379–381
- Matrix metalloproteinases (MMPs), nitrosylation and, 751–752
- MCG-1, mGlu II selective orthosteric agonists, 426–427
- McN-A-343 muscarinic agonist, cardiovascular effects, 176
- Mecamylamine, nicotinic acetylcholine receptors, 121
- Melanocortin, neuropeptide receptors, 690
- Melanocyte-stimulating hormone (MSH), neuropeptides and, 677–678
- Melatonin
  - depression and levels of
    - in menopause, 849–850
    - during menstrual cycle, 844–845
    - postpartum depression, 848
    - in pregnancy, 846–847
  - reproductive-cycle depression and
    - levels of, in menstrual cycle, 844–845
- Membrane-associated guanylate kinase (MAGUK) family, voltage-gated calcium channels,  $\beta$  subunits, 645–646
- Membrane potentials
  - early research on, 25–27
  - inward rectification, with potassium channels, 634–635
- Memory function, muscarinic acetylcholine receptor deficiency, 168–169

- Menopause, neuroendocrine abnormalities and depression in, 849–851
- Menstrual cycle depression, neuroendocrine abnormalities, 844–846, 851
- cortisol, 845
  - melatonin, 844–845
  - prolactin, 846
  - thyroid-stimulating hormone, 845
- Messenger RNA (mRNA)
- D<sub>1</sub> receptor expression, 226–227
  - D<sub>2</sub> receptor expression, 229–230
  - large-conductance calcium-activated potassium channels, structure and function, 630–631
  - mGlu group I selective orthosteric agonists, 423
- Metabotropic receptors
- $\gamma$ -amino butyric acid (GABA) receptors
    - agonists and competitive antagonists, 589–590
    - disease and, 592–597
      - anxiety and depression, 594–595
      - drug addiction, 593–594
      - epilepsy, 595
      - gene linkage studies, 596–597
      - nociception, 595–596
      - therapeutic targeting, GABA<sub>B</sub> receptors, 592–593
      - tumor cell growth and migration, 596
    - effector systems, 580–583
      - adenylate cyclase, 582–583
      - calcium channels, 581–582
      - G-protein-dependent/independent GABA<sub>B</sub> effects, 580–581
      - MAPKs, 583
      - potassium channels, 582
    - endogenous GABA<sub>B</sub> ligands, 588–589
    - GABA<sub>B</sub> deficient mice, 587–588
    - GABA<sub>B</sub> novel compounds, 590–592
    - GABA<sub>B</sub> receptor modulation, 584–586
      - extracellular calcium, 584
      - interacting proteins, 585–587
      - phosphorylation and desensitization, 584–585
    - research background, 570–571
    - structural properties, 571–580
      - allosteric interactions, 580
      - expression cloning, 571–572
      - G-protein coupling determinants, 579–580
      - liganding binding sites, 578–579
      - molecular subtypes, 572–575
      - surface trafficking and heteromerization, 575–578
  - glutamate receptors
    - allosteric potentiators and antagonists
      - mGlu1 antagonists, 436–437
      - mGlu2/3 antagonists, 439–440
      - mGlu5 antagonists, 443–445
      - mGlu7 antagonists, 445
      - mGlu1 potentiators, 435–436
      - mGlu2 potentiators, 437–439
      - mGlu4 potentiators, 440–441
      - mGlu5 potentiators, 441–443
    - background and classification, 421–422
    - future research issues, 445–446
    - orthosteric agents
      - group III selective agonists, 431–433
      - group III selective antagonists, 433–435
      - group II selective agonists, 426–429
      - group II selective antagonists, 429–431
      - group I selective agonists, 423–424
      - group I selective antagonists, 424–426
- Metal ions, voltage-gated calcium channel blockers, 647
- Methamphetamine, histaminergic neuron activity, 327
- 3-Methoxy-4-hydroxyphenol-glycol (MHPG), norepinephrine neurochemistry, 198–199
- 3-(2-Methoxy-phenyl)-
  - 5-methyl-6-phenyl-5*H*-isoxazolol [4,5-*c*]pyridin-4-one, mGlu7 allosteric antagonists, 445
- (2*S*,1'*S*,2'*S*)-2-Methyl-2(2'-carboxycyclopropyl)glycine (MCCG), mGlu II selective orthosteric antagonists, 429–430
- S- $\alpha$ -Methyl-4-carboxyphenylglycine (S-MCPG), mGlu I selective orthosteric antagonists, 425
- Methyl methanethiosulfonate, nitrosothiol detection, 748
- 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), Parkinson's disease and, 755
- (*R,S*)- $\alpha$ -Methyl-4-phosphonophenylglycine (MPPG), mGlu III selective orthosteric agonists, 434–435
- MGS0028, mGlu II selective orthosteric agonists, 429

- MGS0039, mGlu II selective orthosteric antagonists, 431
- Microdomains, dopamine, 233–234
- Miniature end-plate potentials (MEPPS), early research on, 26–27
- Mitogen-activated protein kinase (MAPK)
  - $\alpha_1$  adrenergic receptor signal transduction pathways, 203
  - GABA<sub>B</sub> receptors, effector systems, 583
  - lithium mechanism in bipolar disorder patients, 867–869
  - muscarinic acetylcholine receptor modulation, 159
  - phosphorylation, 89–90
  - receptor-like PTPs, 92–94
  - small G proteins, 63–64
- Monoamine oxidase B (MAOB), Parkinson's disease and, 755
- Monoamine oxidase (MAO)
  - $\alpha_2$ -adrenergic receptor regulation, 205–206
  - dopamine inhibition, 223–224
  - mGlu5 allosteric antagonists, 443–444
  - norepinephrine neurochemistry, 198–199
  - serotonin degradation and reuptake, 261–262
- Monoamines
  - antidepressants and, hippocampal neurogenesis and, 822–823
  - neurotransmitter inactivation, 51–52
  - plasma membrane transporters, 719–720
  - stress and depression convergence in, 825–826
  - vesicular monoamine neurotransmitter transporters, 716–717, 723
- Mood disorders. *See also* specific disorders, e.g. Depression
  - neurotrophic factors
    - antidepressants
      - BDNR expression and, 804–806
      - neurogenesis and, 806–808
    - behavioral effects, 808–809
    - brain-derived neurotrophic factor
      - genetics, 803
    - depressed patients, 800–802
      - structural and cellular alterations, 802–803
    - intracellular signaling cascades, 791–794
      - fibroblast growth factor, 793
      - insulin/insulin-like growth factor, 793
      - nerve growth factor family, 791–792
      - transforming growth factor-beta, 793–794
      - vascular endothelial growth factor, 792–793
    - research background, 790
    - stress and, 794–797
      - adrenal glucocorticoids, 796–797
      - adult neurogenesis and morphology, 797–800
        - hippocampus, 798
      - alterations in, 794–795
      - brain-derived neurotrophic factor, 794–796
      - cytokines, 797
      - glial proliferation, 800
      - serotonin receptors, 797
      - vascular endothelial growth factor, 797
- Morphometric studies, depressed patients, neurotrophic factors and, 802–803
- Motor neuron diseases, plasma membrane glutamate transporter, 718–719
- MPEP
  - mGlu4 allosteric antagonists, 440–441
  - mGlu5 allosteric antagonists, 443–444
- MTEP, mGlu5 allosteric antagonists, 444
- MthK channel, gating mechanism, 626–627
- Multifocal leukoencephalopathy (PML), 5-HT<sub>2A</sub> receptors and, 271
- Multiple sclerosis (MS)
  - nitric oxide physiology, 745
  - voltage-gated sodium ion channels, 640–641
- Muscarinic acetylcholine receptors (mAChRs)
  - activation mechanisms, 155
  - dimerization, 166–127
  - distribution, 149
  - G-protein coupling properties, 155–157
    - RGS proteins, 158
  - G protein selectivity, 157–158
  - ion channels, 160–162
  - ligand binding mechanisms, 152–154
    - agonists, 152
    - allosteric ligands, 153–154
    - antagonists, 152–153
    - clinical applications, 154
  - MAPK pathways modulation, 159
  - phenotypic mouse analysis, 167–177

- agonist-induced tremor and
  - hypothermia, 170–171
- amylase secretion, exocrine pancreas, 175
- analgesia, 170
- autoreceptors, 171
- cardiovascular system, 175–176
- cytolytic T cells, 177
- drug abuse effects, 173
- epileptic seizures, 169
- food intake stimulation, 171
- gastric acid secretion, 175
- inhibitory hippocampal synapse
  - suppression, 172
- learning and memory functions,
  - 168–169
- locomotor activity, 169–170
- nucleus accumbens, dopamine effects,
  - 172–173
- pancreatic islet insulin and glucagon
  - secretion, 174–175
- peripheral autoreceptors and
  - heteroreceptors, 176
- prepulse inhibition and
  - haloperidol-induced catalepsy, 172
- salivary secretion, 174
- skin functions, 177
- smooth muscle functions, 173–174
- striatal dopamine release modulation,
  - 171–172
- regulatory mechanisms, 162–166
  - downregulation, 163–164
  - internatizations, 162–163
  - phosphorylation, 164–166
  - resensitization, 166
  - uncoupling, 162
- research background, 148–149
- signaling pathways, 158–159
- structural features, 149–151
- Mutagenesis
  - GABA<sub>A</sub> receptor activation
    - benzodiazepine binding sites, 506–507, 509–511
    - channel gating binding, 496–497
  - potassium channels, voltage activation, 625–626
- Mutations, in G proteins, 66
- Myotonias, voltage-gated sodium ion
  - channels and, 641–642
- Myristoylated alanine rich C-kinase
  - substrate (MARCKS), lithium
    - mechanism in bipolar disorder
      - patients, 868–869
- National Institute for Medical Research,
  - establishment of, 17–18
- Natural products, AMPA receptor
  - orthosteric agonists, 376–377
- Negative modulators
  - GABA<sub>A</sub>  $\alpha_1$  subunit pharmacology, 488
  - GABA<sub>A</sub>  $\delta$  subunit pharmacology, 492
  - GABA<sub>A</sub>  $\gamma$  subunit pharmacology, 491
  - GABA<sub>A</sub> subunit pharmacology, 483
- Neodysiherbaine, kainate receptor
  - orthosteric agonists, 380
- Nerve growth factor (NGF) family,
  - receptors and kinases in, 791–792
- Nerve injury, voltage-gated sodium ion
  - channels, 640–641
- N*-ethylmaleimide-sensitive factor (NSF)
  - GABA<sub>A</sub> receptor trafficking, 480
  - nitrosylation and, 751
- Neuroanatomy, bipolar disorder, 860–861
- Neurochemistry, bipolar disorder, 861–862
- Neurodegeneration, nitric oxide and, 754
- Neuroendocrine compounds
  - circadian studies of reproductive cycle
    - depression
      - cross-reproductive cycle analysis, 851–853
    - menopause, 849–851
      - cortisol, 850
      - melatonin, 849–850
      - prolactin, 850–851
      - thyroid-stimulating hormone, 850
    - menstrual cycle, 844–846
      - cortisol, 845
      - melatonin, 844–845
      - prolactin, 846
      - thyroid-stimulating hormone, 845
    - postpartum depression, 848–849
      - cortisol, 848
      - estradiol, 849
      - melatonin, 848
      - prolactin, 848–849
      - thyroid-stimulating hormone, 848
    - pregnancy, 846–847
      - cortisol, 847
      - melatonin, 846–847
      - prolactin, 847
      - thyroid-stimulating hormone, 847
    - research background, 844
    - neuropeptide electrophysiology, 675–676
- Neurogenesis
  - adult stages of, 827–829

- antidepressant influences on, 806–808
  - serotonin/norepinephrine regulation, 831–833
  - stress and
    - hormone regulation, 829–830
    - neurotrophins and, 797–800
  - Neurohypophyseal gene family,
    - neuropeptides and, 682–684
  - Neurological disorders
    - GABA transporters and, 722
    - monoamine plasma membrane transporters, 719–720
  - Neuromodulators, neuropeptides as, 676–677
  - Neuromuscular transmission
    - early research on, 12–13
    - Eccles, Kuffler, and Katz research on, 22–23, 25–26
    - electric organ model of, 22
    - Kuffler's research on, 32–33
    - Loewi's experiments in, 18–19
    - Nachmansohn's research on, 23
    - Nobel Prize awarded for research on, 21–22
    - voltage-gated sodium ion channel trafficking, 638–639
  - Neuronal nicotinic receptors
    - history of, 107–108
    - overview, 110–111
    - pharmacology of subtypes, 113–125
  - Neuronal organization
    - adult neurogenesis and, 829
    - histaminergic systems, 301–305
      - afferents, 303–305
      - histaminergic pathways, 303
    - neuron activity and control, 317–322
      - electrophysiology, 317
      - pharmacological changes, 321–322
      - in vitro modulation, 317–319
      - in vivo changes, 319–321
    - perikarya, 301–303
  - KCNQ channel action on, 632–633
  - large-conductance calcium-activated
    - potassium channels, structure and function, 630–631
  - stress and, 800
  - voltage-gated sodium ion channels, 639–640
- "Neuron doctrine," basic principles of, 40–41
- Neuropeptides
- administration, 693
  - basic principles, 670–671
  - behavioral techniques, 677–678
  - biosynthesis and processing, 685–687
    - preprohormones, 686
    - prohormones, 686
    - tissue specificity, 687
  - blood-brain barrier, 692–693
  - classification table, 672–673
  - electrophysiological techniques, 675–677
    - neurohormones, 675–676
    - neuromodulators, 676–677
    - neurotransmitters, 676
  - evolution, 679–685
    - gene duplication, 680–685
    - gene splicing, 685
    - neurohypophyseal family, 682–684
    - NPY family, 684
    - opioid family, 680–682
    - structural conservation, 679–680
  - extracellular inactivation, 687–688
  - future research issues, 695
  - gene isolation and expression, 685
  - genetic manipulations, 678–679
    - knockout mice, 678
    - transgenic animals, 678
  - genomics, 678–679
  - hypothalamic control of pituitary gland, 691–692
  - hypothalamic-pituitary pathways, 692
  - hypothalamic release-stimulating/
    - release-inhibiting actions, 691
  - identification, 671–674
  - inactivation, 687–688
  - intercellular signaling, 44–45
  - intracellular degradation, 687
  - isolation and characterization, 674
  - peptidomics, 675, 679
  - perfusion and tissue culture studies, 677
  - physiological/peptidomic/genomic
    - techniques, 679
  - prolactin release, 691–692
  - receptors
    - agonists/antagonists, 675
    - arginine vasopressin, 689
    - cytokines, 691
    - downregulation and desensitization, 688–689
    - G-protein-coupled receptors, 690
    - guanylate cyclase (cGMP) receptors, 691

- isoreceptors, 689
- melanocortin, 690
- neuropeptide Y system, 689
- phospholipase-phosphatidylinositol-linked messengers, 690
- second-messenger systems and, 690–691
- structure and function, 688–690
- tachykinin, 689–690
- tyrosine kinase-coupled receptors, 691
  - upregulation and sensitization, 689
- redundancy, 694
- site-directed mutagenesis, 679
- stress/neuronal response, 694–695
- time- and tissue-sensitive responses to, 693–694
- Neuropeptide Y system
  - gene duplication and divergence in, 684
  - in knockout mice, 678
  - neuropeptide receptors, 689
  - physiology, 679
- Neuropharmacology
  - Bovet's contributions to, 25
  - Forster's contributions in, 9–11
  - Gaskell and Langley's contributions to, 11–13
  - postwar trends in, 24–25
- Neuropsychiatric disease. *See also* Mood disorders
  - AMPA receptor allosteric potentiators, 394–395
  - GABA<sub>A</sub> subunit pharmacology, allosteric ligand modulation, 505–506
  - histaminergic neuron activity, 321–322, 327–329
    - Alzheimer's disease, 327–328
    - Parkinson's disease, 328
    - schizophrenia and antipsychotics, 326
  - monoamine plasma membrane transporters, 719–720
  - plasma membrane glutamate transporter, 718–719
  - vesicular transporters and, 723
- Neurosteroids
  - GABA<sub>A</sub>  $\delta$  subunit pharmacology, 491–492
  - GABA<sub>A</sub> modulation, 511–516
    - transmembrane domains, 518
- Neurotoxins
  - AMPA receptor orthosteric agonists, 376–377
  - sodium voltage-gated ion channels, 636
  - voltage-gated calcium ion channels, Ca<sub>v</sub>2 family, 649
  - voltage-gated potassium channels, K<sub>v</sub> subunits, structure and function, 630
  - voltage-gated sodium channels and, 642–643
- Neurotransmitters
  - biosynthesis of, 42–43
  - dopaminergic
    - attention-deficit hyperactivity disorder, 237–238
    - basic properties, 221–222
    - bipolar disorders, 237
    - chemistry and metabolism, 222–224
    - classification and molecular properties, 225–230
      - D<sub>1</sub> receptor subfamily, 225–227
      - D<sub>2</sub> receptor subfamily, 227–230
    - drug applications, 236–239
    - Parkinson's disease, 236
    - polymorphisms, splice variants and SNPs, 234–236
    - schizophrenia, 237
    - signal transduction pathways, 230–232
    - structure-affinity/structure-activity relationships, 232–234
    - substance abuse, 238
  - GABA<sub>A</sub> receptor trafficking, 480
  - inactivation, 51–52
  - neuropeptide electrophysiology, 675–676
  - transporters
    - clinical relevance, 718–723
      - dopamine, 721
      - GABA transporters, 721–722
      - glycine transporters, 722–723
      - monoamine transporters, 719–720
      - norepinephrine, 721
      - plasma membrane, 718–721
      - serotonin, 720
      - system interactions, 723
    - early research, 706–707
    - plasma membrane family, 707–715
      - choline, 714–715
      - clinical relevance, 718–723
      - dopamine, 712–713, 721
      - GABA transporters, 711–712, 721–722
      - glutamate transporters, 708–711, 718–719

- glutamine, 715
- glycine transporters, 712, 722–723
- monoamine transporters, 719–720
- norepinephrine, 713–714, 721
- regulation, 724–728
- serotonin, 714, 720
- sodium/chloride-dependent transporters, 711–714
- vesicular transporters, 715–718
  - acetylcholine and monoamine transporters, 716–718
  - clinical relevance, 723
  - glutamate transporters, 716
  - inhibitor amino acid transporters, 718
- voltage-gated calcium ion channels, Ca<sub>v</sub>2 family, 648–649
- voltage-gated potassium channels, K<sub>v</sub> subunits, structure and function, 628–630
- Neurotrophic factors
  - intercellular signaling, 44–45
  - mood disorders
    - antidepressants
      - BDNR expression and, 804–806
      - neurogenesis and, 806–808
    - behavioral effects, 808–809
    - brain-derived neurotrophic factor
      - genetics, 803
    - depressed patients, 800–802
      - structural and cellular alterations, 802–803
    - intracellular signaling cascades, 791–794
      - fibroblast growth factor, 793
      - insulin/insulin-like growth factor, 793
      - nerve growth factor family, 791–792
      - transforming growth factor-beta, 793–794
      - vascular endothelial growth factor, 792–793
    - research background, 790
    - stress and, 794–797
      - adrenal glucocorticoids, 796–797
      - adult neurogenesis and morphology, 797–800
      - hippocampus, 798
      - alterations in, 794–795
      - brain-derived neurotrophic factor, 794–796
      - cytokines, 797
      - glial proliferation, 800
      - serotonin receptors, 797
      - vascular endothelial growth factor, 797
  - Neurotrophin-3 (NT-3), intracellular signaling, 791–792
  - Neurotrophin-4 (NT-4), intracellular signaling, 791–792
  - Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase channel, structure and function, 649–650
  - Nicotine, early research on, 11–12
  - Nicotinic acetylcholine receptor (nAChR)
    - action potential research and, 26–27
    - agonist-induced upregulation, 127–130
    - cloning of, 27–28
    - GABA<sub>A</sub> receptor structure and, 475
    - heteromeric structures, 116–125
    - α<sub>7</sub>nAChR subunit, 114–116
    - overview, 110–111
    - pharmacology of subtypes, 113–125
    - regulation of, 125–130
      - agonist-induced upregulation, 127–130
      - desensitization and inactivation, 125–127
      - structure of, 111–113
      - + TC actions and, 27
  - Nicotinic acetylcholine receptors (nAChRs), history of, 107–110
  - Nicotinic receptors, histaminergic neuron activity, 321–322
  - Nitric oxide (NO), gaseous signaling
    - basic principles, 743–744
    - neurodegeneration and, 754
    - nitrosothiol detection, 747–748
    - nitrosylation mechanism, 745–747
      - cell survival, 752
      - extracellular matrix, 751–752
      - gene transport, 750–751
      - ion channels, 748–749
      - Parkinson's disease and, 755–756
      - protein-protein interactions, 749–750
      - S nitrosylation physiology, 752–754
      - vesicular transport, 751
    - physiological role, 745
  - Nitric oxide synthases (NOSs), nitric oxide synthesis, 743–744
  - S-Nitrosocysteinyl glycine (CGSNO), nitric oxide nitrosylation, 747
  - S-Nitrosoglutathione (GSNO), nitric oxide nitrosylation, 747

- S-Nitrosoglutathione reductase (GSNOR), nitric oxide nitrosylation, 747
- Nitrosothiols  
 nitric oxide gaseous signaling, 747–748  
 S nitrosylation physiology and, 753–754
- Nitrosylation, nitric oxide gaseous signaling, 745–747  
 cell survival, 752  
 extracellular matrix, 751–752  
 gene transport, 750–751  
 ion channels, 748–749  
 Parkinson's disease and, 755–756  
 protein-protein interactions, 749–750  
 S nitrosylation physiology, 752–754  
 vesicular transport, 751
- NMDA (*N*-methyl-D-aspartic acid) receptors  
 allosteric antagonists, 386–390  
 allosteric potentiators, 385–396  
 in bipolar disorder patients, 863  
 lithium mechanisms, 868–869  
 GABA<sub>B</sub> receptor trafficking and heteromization, 575–576  
 histamine receptor interaction, 316–317  
 mGlu5 allosteric antagonists, 443–444  
 mGlu group I selective orthosteric agonists, 424  
 nitric oxide physiology, 745  
 nitrosylation, 748–749  
 orthosteric agonists, 373  
 orthosteric antagonists, 373–376  
 stress and neurogenesis and, 799–800  
 structure and function, 367–370  
 voltage-gated potassium channels, K<sub>V</sub> subunits, structure and function, 629–630
- Noceptin, histaminergic neuron activity, 319
- Nociception  
 GABA<sub>B</sub> receptor targeting, 595–596  
 histamine neuron physiology, 326  
 voltage-gated calcium ion channels, Ca<sub>v</sub>2 family, 649
- Norepinephrine (noradrenaline)  
 α-adrenergic receptors, α<sub>2</sub>-adrenergic receptor, 204–209  
 β-adrenergic receptor activation, 209–210  
 antidepressant influences on, hippocampal neurogenesis and, monoamines, 822–823  
 basic properties, 193  
 dopamine synthesis, 56, 223–224  
 early research on, 29–30  
 historical perspective, 194–196  
 mood disorders and, basic principles, 790  
 neurochemistry, 198–199  
 neurogenesis regulation, 831–833  
 neurotransmitter transporters  
 chronic substrate treatment, 726–727  
 clinical relevance, 721  
 structure and function, 713–714  
 physiology, 197–198
- Norepinephrine transporter (NET)  
 agent selectivity, 199–200  
 general characteristics, 199–200  
 genetic variations, 200–201
- NS3763, kainate receptor allosteric antagonists, 397
- Nuclear receptors, chemical release, 48–50
- Nucleus accumbens, muscarinic acetylcholine receptor deficiency, dopamine efflux, 172–173
- Nucleus basalis magnocellularis, H<sub>1</sub> receptors in, 311
- Null modulators, GABA<sub>A</sub> subunit pharmacology, 483
- Obsessive compulsive disorder (OCD), serotonin transporters and, 720
- Ocinaplon, GABA<sub>A</sub> α<sub>2</sub> subunit pharmacology, 488  
 allosteric ligand modulation, 505–506
- Oocyte expression systems, heteromeric nicotinic acetylcholine, 117–119
- Opioid family, neuropeptide gene duplication in, 680–682
- Opioid receptor agonists, histaminergic neuron activity, 321–322
- Orexins, histaminergic neuron activity, 318–319, 320–322
- Organic cation transporters (OCT), histamine inactivation, 307
- Orthostatic intolerance, norepinephrine transporters and, 721
- Orthosteric agents  
 ionotropic glutamate receptors, 373–385  
 AMPA receptor agonists, 376–377  
 AMPA receptor antagonists, 377–378  
 kainate receptor agonists, 378–381  
 kainate receptor antagonists, 381–385  
 NMDA receptor agonists, 373  
 NMDA receptor antagonists, 373–376  
 metabotropic glutamate receptors

- group III selective agonists, 431–433
- group III selective antagonists, 433–435
- group II selective agonists, 426–429
- group II selective antagonists, 429–431
- group I selective agonists, 423–424
- group I selective antagonists, 424–426
- Oxine derivatives, kainate receptor orthosteric antagonists, 381–382
- 2-Oxoglutarate (2-OG), plasma membrane glutamate transporters, 711
- Oxygen
  - nitric oxide gaseous signaling, nitrosylation, 746–747
  - S nitrosylation physiology and, 752–754
- Oxyhemoglobin, S nitrosylation physiology and, 752–754
- Oxytocin, neuropeptides and, 682–684
  
- Pain management
  - mGlu1 allosteric antagonists, 437
  - voltage-gated calcium ion channels, Ca<sub>v</sub>2 family, 649
- Pancreatic islets, muscarinic acetylcholine receptor deficiency, 174–175
- Paralytic disorders, voltage-gated sodium ion channels and, 641–642
- Parkinson's disease
  - dopaminergic drugs, 236
  - dopamine transporters and, 721
  - histaminergic neuron activity, 328
  - nitric oxide and, 754–755
  - nitrosylation and, 755–756
  - plasma membrane glutamate transporter, 719
- Parvicellular system, hypothalamic-pituitary pathways, 692
- Peptide toxins
  - large-conductance calcium-activated potassium channels, 631
  - small-conductance calcium-activated potassium channels, 632
  - voltage-gated potassium channels, K<sub>v</sub> subunits, structure and function, 630
- Peptide transmitters, intercellular signaling, 46
- Peptide transport systems, blood-brain barrier neuropeptides and, 692–693
- Peptidomics, neuropeptides, 675, 679
  
- Perfusion and tissue culture studies, neuropeptides, 677
- Periodic paralysis, voltage-gated sodium ion channels and, 641–642
- Peripheral nervous system
  - in bipolar disorder patients, 863–864
  - kainate receptors, 372
  - voltage-gated sodium ion channels, 640
- Peroxisomal proliferation activating receptors (PPARs), mGlu2 allosteric potentiators, 439
- Pharmacology, early research in, 11
- PHCCC, mGlu4 allosteric antagonists, 440–441
- Phencyclidine (PCP)
  - mGlu II selective orthosteric agonists, 428–429
  - mGlu II selective orthosteric antagonists, 430–431
  - NMDA receptors, 368–370
- Phenotypic mice, muscarinic acetylcholine receptor deficiency, 167–177
  - agonist-induced tremor and hypothermia, 170–171
  - amylase secretion, exocrine pancreas, 175
  - analgesia, 170
  - autoreceptors, 171
  - cardiovascular system, 175–176
  - cytolytic T cells, 177
  - drug abuse effects, 173
  - epileptic seizures, 169
  - food intake stimulation, 171
  - gastric acid secretion, 175
  - inhibitory hippocampal synapse suppression, 172
  - learning and memory functions, 168–169
  - locomotor activity, 169–170
  - nucleus accumbens, dopamine effects, 172–173
  - pancreatic islet insulin and glucagon secretion, 174–175
  - peripheral autoreceptors and heteroreceptors, 176
  - prepulse inhibition and haloperidol-induced catalepsy, 172
  - salivary secretion, 174
  - skin functions, 177
  - smooth muscle functions, 173–174
  - striatal dopamine release modulation, 171–172

- Phenyl-terazolyl acetophenone, mGlu2 allosteric potentiators, 439
- Phosphatase and tensin homolog (PTEN), receptor-like PTPs, 94
- Phosphoinositide signaling molecules, intracellular signaling, 81–83
- Phospholipase-phosphatidylinositol-linked messengers, neuropeptide receptors, 690
- Phosphorylase, glycogen breakdown, 31–32
- Phosphorylation  
 cyclic nucleotide second messenger signaling, guanylyl cyclases, 78–80  
 GABA<sub>A</sub> receptor modulation, 481–482  
 GABA<sub>B</sub> receptors, 584–585  
 muscarinic acetylcholine receptors, 164–166  
 of proteins, intracellular signaling, synaptic transmission, 87–96  
 G-protein-coupled receptor kinases, 90–92  
 mitogen-activated protein kinase, 89–90  
 protein tyrosine kinase, 87–89  
 protein tyrosines phosphatases, 92–94  
 serine/threonine phosphatases, 94–96
- Phylogenetic tree, potassium channels, 623–625
- Picrotoxin, GABA<sub>A</sub> receptor inhibition, 468–469
- Pinocytosis, blood-brain barrier neuropeptides and, 692–693
- Pituitary adenylate cyclase-activating polypeptide (PACAP)  
 lithium mechanism in bipolar disorder and, 867–869  
 neuropeptide hypothalamic control, 691–692
- Pituitary gland, neuropeptide hypothalamic control of, 691–692
- Pituitary hormones, histamine neuron physiology and secretion of, 324–325
- Plant products  
 GABA<sub>A</sub> subunit pharmacology, allosteric ligand modulation, 505–506  
 neuropharmacological research and role of, 6  
 tubocurarine, small-conductance calcium-activated potassium channels, 632
- Plasma membrane neurotransmitters, GABA transporters and, 467–468
- Plasma membrane neurotransmitter transporter families, 707–715  
 choline, 714–715  
 clinical relevance, 718–723  
 dopamine, 721  
 GABA transporters, 721–722  
 glycine, 722–723  
 monoamine, 719–721  
 norepinephrine, 721  
 serotonin, 720  
 dopamine, 712–713, 721  
 GABA transporters, 711–712, 721–722  
 glutamate transporters, 708–711, 718–719  
 glutamine, 715  
 glycine transporters, 712, 722–723  
 monoamine transporters, 719–720  
 norepinephrine, 713–714, 721  
 regulation, 724–728  
 chronic substrate treatment, 726–727  
 multiple transcription initiation sites, 725–726  
 polymorphisms, 724–725  
 second messengers, 727–728  
 serotonin, 714, 720  
 sodium/chloride-dependent transporters, 711–714  
 dopamine transporters, 712–713  
 GABA transporters, 711–712  
 glycine transporters, 712  
 norepinephrine transporters, 713–714  
 serotonin transporters, 714  
 structure and function, 707–708
- Plic-1 protein, GABA<sub>A</sub> receptor trafficking, 480
- Polyamines, NMDA receptor allosteric antagonists, 389
- Polymorphisms  
 dopamine, 234–236  
 plasma membrane neurotransmitter transporter regulation, 724–725
- Population growth, impact on science of, 7–9
- Positive modulators  
 GABA<sub>A</sub>  $\alpha_1$  subunit pharmacology, 488  
 GABA<sub>A</sub>  $\delta$  subunit pharmacology, 492  
 GABA<sub>A</sub>  $\gamma$  subunit pharmacology, 491  
 GABA<sub>A</sub> receptor activation, allosteric ligands, 503–506  
 GABA<sub>A</sub> subunit pharmacology, 483
- Postmortem studies, depressed patients, neurotrophic factors and, 800–803

- Postmortem studies, bipolar disorder, 860–861
- Postpartum depression, neuroendocrine abnormalities and, 848–849, 851
- Postsynaptic density protein (PSD), GABA<sub>B</sub> receptor modulation, 586–587
- Postsynaptic receptors  
 GABA<sub>A</sub> receptor distribution, 474–475  
 GABA<sub>B</sub> receptor subtypes, 573–575  
 intercellular signaling, 48–50
- Posttraumatic stress disorder (PTSD), stress-monoamine convergence, 826
- Potassium channels  
 early research on, 25  
 GABA<sub>B</sub> receptors, effector systems, 582  
 histaminergic neuron activity, 317–319  
 muscarinic acetylcholine receptor modulation, 160–161  
 voltage-gated ion channels, 621–635  
   calcium activation, 630–632  
   fast inactivation, 627  
   gating, 626–627  
   genetics, 619–620  
   interacting proteins, 627–628  
   inwardly-rectifying and two-P channels, 634–635  
   KCNH channels, 633–634  
   KCNQ family, 632–633  
   K<sub>v</sub> subunits, 628–630  
   K<sub>v</sub> subunits, structure and function, 628–630  
   physiology, disease and pharmacology, 628–634  
   selectivity, 623–625  
   voltage activation, 625–626
- Pregnancy, depression in, neuroendocrine abnormalities and, 846–847, 851
- Pregnanolone sulfate  
 GABA<sub>A</sub>  $\delta$  subunit pharmacology, 492  
 GABA<sub>A</sub> receptor modulation, 515
- Premenstrual cycle depressive disorder (PMDD). *See* Menstrual cycle depression
- Preprohormones, neuropeptide biosynthesis and, 686
- Prepulse inhibition  
 mGlu5 allosteric potentiators, 443  
 muscarinic acetylcholine receptor deficiency, 172
- Presynaptic receptors  
 $\alpha_2$  adrenergic receptor physiology, 208–209  
 GABA<sub>A</sub> receptor distribution, 474–475  
 GABA<sub>B</sub> receptor subtypes, 573–575  
 histaminergic neuron activity, 321–322  
 intercellular signaling, 50–51
- Prohormones, neuropeptide biosynthesis and, 686
- Prolactin release  
 depression and levels of  
   in menopause, 850–851  
   during menstrual cycle, 846  
   postpartum depression, 848–849  
   in pregnancy, 847  
 neuropeptides, 691–692
- Promoter regions, plasma membrane transporter regulation, 725
- Pro-opiomelanocortin (POMC)  
 gene organization and expression, 685  
 neuropeptide gene duplication, 680–682
- Propranolol,  $\beta$ -adrenergic receptor activation, 210
- Protein kinase A (PKA)  
 in bipolar disorder patients, 862  
 cyclic nucleotide second messenger signaling, cAMP cellular targeting, 75, 78  
 GABA<sub>A</sub> receptor phosphorylation, 481–482  
 GABA<sub>B</sub> receptor desensitization and phosphorylation, 584–585
- Protein kinase C (PKC)  
 amino acid neurotransmitters, 43–44  
 DAG activation, 85  
 GABA<sub>A</sub> receptor phosphorylation, 481–482  
 GABA<sub>B</sub> receptor desensitization and phosphorylation, 584–585  
 GABA transporters, 467–468  
 heterotrimeric G proteins, 62–63  
 H<sub>1</sub> receptor signaling, 309–311  
 muscarinic acetylcholine receptor phosphorylation, 164
- Protein-protein interactions. *See also* Interacting proteins  
 G-protein coupled receptors, 70–71  
 nitrosylation and, 749–750
- Protein tyrosine kinases (PTKs), phosphorylation, 87–89
- Protein tyrosine phosphatases (PTPs), phosphorylation, 92–94
- Pseudogenes, D<sub>1</sub> receptor expression, 227

- Purines, packaging of, 46
- Pyramidal neurons, 5-HT<sub>2A</sub> receptors in, 270–271
- Pyrethroid insecticides, voltage-gated sodium ion channels and, 643
- Pyridoindole, GABA<sub>A</sub> subunit pharmacology, allosteric ligand modulation, 504–506
- Pyrrolidinones, AMPA receptor allosteric potentiators, 390
- Quinidine, voltage-gated potassium channels, K<sub>V</sub> subunits, structure and function, 630
- Quinoazolines, AMPA receptor allosteric antagonists, 395–396
- Quinoxalinediones, kainate receptor orthosteric antagonists, 383
- Quinoxalines, AMPA receptor orthosteric antagonists, 377
- Quisqualate, mGlu group I selective orthosteric agonists, 423
- Radioimmunoassay (RIA), neuropeptide identification, 673
- Receptor activity modifying proteins (RAMPs), GABA<sub>B</sub> receptor modulation, 585–586
- Receptor for activated C kinase (RACK-1), GABA<sub>A</sub> phosphorylation, 482
- Receptor-like PTPs (RPTPs), phosphorylation, 92–94
- Receptors, serotonin family, 262–264
- Receptor tyrosine kinases (RTKs), signaling pathways, 88–89
- Redundancy, of neuropeptides, 694
- Reelin mRNA, in bipolar disorder patients, 862
- Release-inhibiting factor, neuropeptide hypothalamic control, 691–692
- Release-stimulating hormones, neuropeptide hypothalamic control, 691–692
- Repolarization, voltage-gated potassium channels, K<sub>V</sub> subunits, structure and function, 628–630
- Reproductive cycle depression, neuroendocrine studies  
cross-reproductive cycle analysis, 851–853  
future research issues, 852–853  
menopause, 849–851  
cortisol, 850  
melatonin, 849–850  
prolactin, 850–851  
thyroid-stimulating hormone, 850
- menstrual cycle, 844–846  
cortisol, 845  
melatonin, 844–845  
prolactin, 846  
thyroid-stimulating hormone, 845
- postpartum depression, 848–849  
cortisol, 848  
estradiol, 849  
melatonin, 848  
prolactin, 848–849  
thyroid-stimulating hormone, 848
- pregnancy, 846–847  
cortisol, 847  
melatonin, 846–847  
prolactin, 847  
thyroid-stimulating hormone, 847
- research background, 844
- Resensitization, muscarinic acetylcholine receptor phosphorylation, 166
- Reserpine, early research on, 30–31
- Resting membrane potentials, KCNH potassium channels, 633–634
- Reuptake mechanisms  
dopamine synthesis, 55  
serotonin, 261–262
- RGS proteins  
muscarinic acetylcholine receptors, 158  
structure and function, 65–66
- RNA editing, 5-HT<sub>2C</sub> receptors and, 272–273
- Ro 15-4513, GABA<sub>A</sub>  $\alpha_1$  subunit pharmacology, 488
- RO 67-7476/67-4853, mGlu1 allosteric potentiators, 435–436
- RO 718218, mGlu2/3 allosteric antagonists, 439–440
- Romano-Ward syndrome, KCNQ channels and, 632–633
- Rostral agranular insular cortex (RAIC), GABA<sub>B</sub> receptor targeting, 596
- RSSR signaling, GABA<sub>B</sub> receptor trafficking and heteromization, 575–578
- Ryanodine, ion channel nitrosylation, 748–749
- Salivary secretion, muscarinic acetylcholine receptor deficiency, 174
- Satiation, histaminergic neuron activity, 325–326

- Saxitoxin (STX), voltage-gated sodium ion channels and, 642–643
- Scaffolding proteins, voltage-gated potassium channels, 628
- Schizophrenia  
dopaminergic drugs, 237  
histaminergic neuron activity, 327  
5-HT<sub>2A</sub> receptors and, 270–271
- Scientific research  
Dale and Loewi's contributions in, 14–15  
Forster's contributions in, 9–11  
German universities and, 9  
population growth and, 7–9  
postwar trends in, 24–25  
role of patronage in, 7–8  
Wellcome's contributions to, 15
- SCL17 transporter family, 716
- Second-messenger systems  
early research on, 31–32  
glutamate transporter regulation, 727–728  
neuropeptide receptors, 690–691
- Sedative effects  
 $\alpha_2$  adrenergic receptor physiology, 207–208  
GABA<sub>A</sub>  $\beta$  subunit pharmacology, 490–491  
GABA<sub>A</sub>  $\gamma$  subunit pharmacology, 491  
GABA<sub>A</sub> receptor activation, allosteric ligand modulation, 503–506
- Seizure disorders. *See also* Epileptic seizures  
GABA transporters and, 722  
histamine neuron physiology, 326  
KCNQ channels and, 633
- Selectivity  
potassium channels, 623–625  
sodium voltage-gated ion channels, 637
- Serine/threonine phosphatases, phosphorylation, 94–96
- Serotonergic neurons, model of, 264
- Serotonin (5-HT)  
anatomy, 260  
antidepressant influences on, 806–808  
hippocampal neurogenesis and, monoamines, 822–823  
stress-monoamine convergence, 825–826  
basic properties, 257–259  
degradation and reuptake, 261–262  
early history, 30–31, 259–260  
future research on, 276–277  
histaminergic neuron activity, 318–319  
mood disorders and, basic principles, 790  
neurogenesis regulation, 831–833  
neurotransmitter transporters (SERTs)  
chronic substrate treatment, 726–727  
clinical relevance, 720  
glycosylation, 725–726  
multiple transcription initiation sites, 725  
promoter region polymorphisms, 725  
serotonin degradation and reuptake, 261–262  
stress-monoamine convergence in depression, 825–826  
structure and function, 714  
neurotrophins and, stress influence on, 797  
receptors, 262–276  
synthesis, 260–261
- Serotonin reuptake inhibitors (SRIs), hippocampal neurogenesis and depression and, 827
- Serum analysis, brain-derived neurotrophic factor in depressed patients, 801
- Severe myoclonic epilepsy of infancy (SMEI), voltage-gated sodium ion channels and, 642
- Short-term potentiation (STP), muscarinic acetylcholine receptor deficiency, 169
- SIB-1757, mGlu5 allosteric antagonists, 443
- SIB-1893, mGlu4 allosteric antagonists, 440–441
- Signaling molecules  
 $\alpha_1$  adrenergic receptor regulation, 203  
 $\alpha_2$ -adrenergic receptor regulation, 206  
 $\beta$ -adrenergic receptor activation, 210–211  
calcium channels, 83–85  
dopamine, 223–224  
dopamine receptors, 230–232  
GABA<sub>A</sub> phosphorylation, 482  
gaseous signaling  
carbon monoxide, 756–757  
future research, 757  
nitric oxide  
basic principles, 743–744  
neurodegeneration and, 754  
nitrosothiol detection, 747–748  
nitrosylation mechanism, 745–747  
cell survival, 752  
extracellular matrix, 751–752  
gene transport, 750–751  
ion channels, 748–749

- Parkinson's disease and, 755–756
- protein-protein interactions, 749–750
- S nitrosylation physiology, 752–754
- vesicular transport, 751
- physiological role, 745
- research background, 743–744
- H<sub>2</sub> receptor, 312
- H<sub>3</sub> receptor, 314–315
- H<sub>1</sub> receptors, 309
- IP<sub>3</sub> and phosphoinositides, 81–83
- muscarinic acetylcholine receptor modulation, 158–159
- voltage-gated calcium channels, 647
- Single-nucleotide polymorphisms (SNPs)
  - $\beta$ -adrenergic receptor physiology, 212–213
  - dopamine, 234–236
  - plasma membrane neurotransmitter transporter regulation, 724–725
- Site-directed mutagenesis, neuropeptides, 679
- Skeletal muscle, voltage-gated sodium ion channels and, 641–642
- Skin function, muscarinic acetylcholine receptor deficiency, 177
- SLC1 family, plasma membrane glutamate transporters, 708–711
- SLC5 family, structure and function, 714–715
- SLC6 family of neurotransmitters, 711–714
- SLC32 transporter family, 718
- Small-conductance calcium-activated potassium channels (SK channels), structure and function, 631–632
- Small G proteins, structure and function, 63–64
- Smooth muscle function, muscarinic acetylcholine receptor deficiency, 173–174
- S nitrosylation
  - nitric oxide, protein mechanisms, 747
  - physiology of, 752–754
- Sodium channels
  - early research on, 25
  - plasma membrane glutamate transporters, 709–711
  - voltage-gated ion channels, 635–643
    - $\alpha$  subunits, 636–637
    - channelopathies, 641–642
    - genetics, 619–620
    - inactivation, 637–638
    - pharmacology, 642–643
    - physiological functions, 639–641
    - selectivity, 637
    - trafficking, 638–639
- Sodium/chloride-dependent neurotransmitter transporters, 711–714
  - dopamine transporters, 712–713
  - GABA transporters, 711–712
  - glycine transporters, 712
  - norepinephrine transporters, 713–714
  - serotonin transporters, 714
- Soluble N-ethylmaleimide-sensitive factor attachment protein receptors (SNAREs)
  - plasma membrane transporter regulation, 728
  - vesicle-dependent release, 46–47
    - nitrosylation and, 751
- Somatostatin (ST), neuropeptides and, 671
- Somatotropin release-inhibiting factor (SRIF), neuropeptide hypothalamic control, 691–692
- Splice variants, dopamine, 234–236
- 1S,3R-ACPD, mGlu group I selective orthosteric agonists, 423
- Steroid hormones
  - GABA<sub>A</sub>  $\alpha$ <sub>4</sub> subunit pharmacology, 488–489
  - NMDA allosteric potentiators, 386
- Stoichiometry, plasma membrane glutamate transporters, 709–711
- Stress
  - histaminergic neuron activity, 320–322
  - pituitary hormone secretion, 325
  - hormones and, 679
  - neurogenesis regulation, 829–830
  - monoamine hypothesis of depression and, hippocampal neurogenesis and, 825–826
  - neuroendocrine response, 694–695
  - neurotrophic factors and, growth factors, 794–797
    - adrenal glucocorticoids, 796–797
    - adult neurogenesis and morphology, 797–800
    - hippocampus, 798
    - alterations in, 794–795
    - brain-derived neurotrophic factor, 794–796
    - cytokines, 797

- glial proliferation, 800
  - serotonin receptors, 797
  - vascular endothelial growth factor, 797
- Striatal complex
  - dopamine release, muscarinic acetylcholine receptor deficiency, 171–172
  - histaminergic neuron activity, Parkinson's disease, 328
- Stroke therapy
  - GABA transporters and, 722
  - mGlu II selective orthosteric agonists, 428–429
  - mGlu I selective orthosteric antagonists, 425
  - NMDA orthosteric antagonists, 375–377
- Structure-activity relationships
  - dopamine, 232–234
  - mGlu2 allosteric potentiators, 438–439
- Structure-affinity relationships, dopamine, 232–234
- Substance abuse
  - dopaminergic drugs for, 238–239
  - GABA<sub>B</sub> receptor targeting, 593–594
  - 5-HT<sub>2C</sub> receptors and, 272–273
  - muscarinic acetylcholine receptor deficiency, 173
  - serotonin transporters and, 720
- Substance P, neuropeptides and, 670–671
  - neurotransmitters, 676
- Subtype-selective ligands, GABA<sub>B</sub> receptors, 592
- 6-Sulfatoxymelatonin (6-SMT), menopause therapy and, 849–850
- Surface trafficking, GABA<sub>B</sub> receptors, 575–578
- Synapses
  - curare's effect on, 4–7
  - early research on, 13–14
  - Eccles' research on, 28–29
  - electric organ model of, 22
  - Feldberg's research on, 20–21
  - GABA<sub>A</sub> receptor distribution on, 473–475
  - ion channels and, 25
  - Loewi's experiments on, 18–19
  - postwar research on, 24–25
  - serotonergic neurons, 264
- Synaptic release
  - vesicle-dependent release, 46–47
  - vesicle-independent release, 47–48
- voltage-gated sodium ion channels, 639–640
- Synaptic transmission
  - AMPA receptor allosteric potentiators, 394–395
- intercellular signaling
  - basic principles, 40–41
  - classical transmitters, 45–46
  - dopamine neurotransmitters, 54–56
  - endocannabinoids, purines, and gaseous transmitters, 46
  - glutamate neurotransmitters, 52–54
  - peptide transmitters and growth factors, 46
  - postsynaptic receptors, 48–50
  - presynaptic receptors, 50–51
  - synaptic release, 46–48
  - transmitter inactivation, 51–52
  - transmitter packaging, 45–46
  - transmitter synthesis, 41–45
    - amine transmitters, 42–44
    - endocannabinoids, 45
    - gaseous transmitters, 45
    - neuropeptides, neurotrophins, and growth factors, 44–45
  - vesicle-dependent release, 46–47
  - vesicle-independent release, 47–48
- intracellular signaling
  - basic principles, 59–60
  - calcium channel calmodulin mediator, 85–87
  - calcium channel signaling molecules, 83–85
  - cyclic nucleotide second messengers, 72–81
    - adenyl cyclase, 72–77
    - cAMP targets, 75, 78
    - cGMP cellular targets, 80–81
    - guanylyl cyclase, 78–80
  - DAG activation of protein kinase C, 85
  - GPCR-G protein ion channel
    - modulation, 66–71
    - downstream signaling molecules, 69–70
    - G $\beta\gamma$  signaling, 67–69
    - protein-protein interactions, 70–71
  - G protein signal transducers, 60–66
    - cycle regulations, 64–65
    - disease and, 67
    - heterotrimeric protein structure, 60–63
    - RGS proteins, 65–66
    - small proteins, 63–64

- IP<sub>3</sub> and phosphoinositide signaling molecules, 81–83
- protein phosphorylation, 87–96
- G-protein-coupled receptor kinases, 90–92
  - mitogen-activated protein kinase, 89–90
  - protein tyrosine kinase, 87–89
  - protein tyrosines phosphatases, 92–94
  - serine/threonine phosphatases, 94–96
- Synaptic vesicles, early research on, 27
- Synaptotagmin, vesicle-dependent release, 46–47
- Tachykinin, neuropeptide receptors, 689–690
- T-182C polymorphism, norepinephrine transporter genetics, 201
- + TC
- actions of, 27
  - postwar applications of, 25
- Tele*-methylhistamine (*t*-MeHA), histaminergic neuron activity, 319–322
- Tetraethylammonium (TEA), voltage-gated potassium channels, K<sub>V</sub> subunits, structure and function, 630
- Tetrodotoxin (TTX), voltage-gated sodium ion channels and, 642–643
- Thalamic relay neurons, histamine neuron physiology, arousal mechanisms, 322–324
- Thalamic reticular nucleus, GABA<sub>A</sub> α<sub>3</sub> subunit pharmacology, 488
- Therapeutic targeting, GABA<sub>B</sub> receptors, 592–593
- Thyroid hormones, GABA<sub>A</sub> receptor modulation, 520
- Thyroid-stimulating hormone (TSH)
- depression and levels of
    - in menopause, 850
    - during menstrual cycle, 845
    - postpartum depression, 848
    - in pregnancy, 847
  - neuropeptides and, 676–677
- Time-sensitive responses, to neuropeptides, 693–694
- Tissue culture studies
- brain-derived neurotrophic factor in depressed patients, 800–801
  - neuropeptides, 677
- Tissue-specific processing, neuropeptides, 687, 693–694
- Torpedo* electric organ
- GABA<sub>A</sub> receptor structure and, 475
  - nicotinic acetylcholine receptor history, 108–110
  - synapse research and, 22–23
- Torpedo* electric organ model
- nicotinic acetylcholine receptor, 27–28
  - of synapse activity, 22
- Torsade de pointes, KCNQ channels and, 632–633
- Tourette's syndrome, dopaminergic drugs, 237
- Trafficking mechanisms
- GABA<sub>A</sub> receptors, 478–480
  - GABA<sub>B</sub> receptors, 575–578
  - voltage-gated sodium ion channels, 638–639
- TRAM-34 analog,
- intermediate-conductance calcium-activated potassium channels, 631
- Trans*-aminocyclobutanedicarboxylate (ABCD), NMDA orthosteric agonists, 373
- Transcriptional regulation
- α<sub>1</sub> adrenergic receptors, 202–203
  - β-adrenergic receptor physiology, 212–213
  - lithium mechanism in bipolar disorder patients, 867–869
  - nitrosylation and, 750–751
  - plasma membrane transporters, 725
- Transforming growth factor-β (TGF-β), intracellular signaling, 793–794
- Transgenic animals, neuropeptide genetic manipulations in, 678
- Trans-Golgi network (TGN), GABA<sub>B</sub> receptor trafficking and heteromization, 577–578
- Transient receptor potential (TRP) channels
- cyclic nucleotide second messenger signaling, adenylyl cyclase, 74–75
  - structure and function, 649–650
- Translocation, plasma membrane glutamate transporters, 710–711
- Transmembrane diffusion, blood-brain barrier neuropeptides and, 692–693
- Transmembrane domains (TMDs)
- AMPA receptors, 370–371
  - dopamine, 233–234

- GABA<sub>A</sub> receptors  
 allosteric sites in, 516–518  
 allosteric structural determinants,  
 508–509  
 channel gating binding, 495–497  
 desensitization and deactivation, 499  
 subunit gene splicing, 469–470  
 GABA transporters, 467–468  
 mGlu5 allosteric antagonists, 443–444  
 mGlu1 allosteric potentiators, 436  
 muscarinic acetylcholine receptor  
 structure, 149–151  
 plasma membrane glutamate transporters,  
 709–711  
 sodium voltage-gated ion channels, 636  
 voltage-gated calcium channels,  $\gamma$   
 subunits, 646  
 Transmembrane segment (TMS) topology,  
 voltage-gated ion channels, 619–620  
 Transmethylation, histamine inactivation,  
 306–307  
 Transmitter inactivation, intercellular  
 signaling, 51–52  
 Transmitter packaging, classical  
 transmitters, 45–46  
 Transmitter synthesis, intercellular signaling  
 and, 41–45  
 amine transmitters, 42–44  
 endocannabinoids, 45  
 gaseous transmitters, 45  
 neuropeptides, neurotrophins, and growth  
 factors, 44–45  
 Tremor induction, muscarinic acetylcholine  
 receptor deficiency, 170–171  
 Tricarboxylic acid (TCA) cycle, plasma  
 membrane glutamate transporters,  
 711  
 Trichloroethanol, GABA<sub>A</sub> receptor  
 modulation, 516  
 Tricyclic antidepressants, early research on,  
 30–31  
 Tryptophan hydroxylase (TPH), serotonin  
 synthesis, 260–261  
 Tuberosomammillary nucleus  
 histamine neuron physiology  
 arousal mechanisms, 323–324  
 cognitive function, 324  
 histaminergic neuron activity, 319–322  
 histaminergic neurons, 301–303  
 Tubocurarine, small-conductance  
 calcium-activated potassium  
 channels, 632  
 Tumor cell growth and migration  
 GABA<sub>B</sub> receptor targeting, 596  
 KCNH potassium channels, 634  
 Two-P (KCNK) channels, structure and  
 function, 634–635  
 Tyrosine kinase receptors  
 chemical release, 48–50  
 GABA<sub>A</sub> phosphorylation, 482  
 glutamate transporter regulation, 727–728  
 neuropeptide receptors, 691  
 Uncoupling reactions, muscarinic  
 acetylcholine receptors, 162  
 Upregulation, neuropeptide receptors, 689  
*val* alleles, BDNF in mood disorders, 803  
 Variable number of tandem repeats  
 (VNTRs)  
 plasma membrane transporter regulation,  
 725  
 serotonin transporters and, 720  
 Vascular endothelial growth factor (VEGF)  
 antidepressant influences on, 805–806  
 adult neurogenesis and, 807–808  
 depression models and, 809  
 intracellular signaling, 792–793  
 stress influence on, 797  
 neurogenesis and, 799–800  
 Vascular tone,  $\alpha_1$  adrenergic receptor  
 physiology, 203–204  
 Vasoactive intestinal polypeptide (VIP),  
 neuropeptides and, 670–671  
 modulation actions, 677  
 Vasopressin, neuropeptides and  
 gene duplication and, 682–684  
 modulation, 677  
 Vasopressinergic neurons, H<sub>1</sub> receptor  
 signaling, 309  
 Ventrolateral preoptic nucleus (VLPO)  
 histaminergic neuron activity, 319–322  
 histaminergic neurons, 305  
 Vesicle-dependent synaptic release, 46–47  
 Vesicle-independent synaptic release, 47–48  
 Vesicular GABA transporters (VGATs)  
 function of, 466  
 GABA affinity, 467–468  
 Vesicular glutamate transporters (VGLUT)  
 glutamate synthesis and storage, 366  
 neurotransmitter functions,  
 716, 723  
 Vesicular inhibitory amino acid transporters,  
 structure and function, 718

- Vesicular monoamine transporter 2 (VMAT 2)  
 chronic substrate treatment, 726–727  
 histamine metabolism, 306  
 neurotransmitter functions, 716–717, 723
- Vesicular neurotransmitter transporters, 715–718  
 acetylcholine and monoamine transporters, 716–718  
 clinical relevance, 723  
 glutamate transporters, 716  
 inhibitor amino acid transporters, 718  
 nitrosylation and, 751
- Vogel conflict model, mGlu5 allosteric antagonists, 444
- Voltage activation, potassium channels, 625–626
- Voltage-gated calcium channels (VGCCs)  
 downstream signaling, 69–70  
 signal modulation, 68–69
- Voltage-gated ion channels  
 calcium channels, 643–650  
 $\alpha$  subunits, 644–645  
 $\alpha\delta$  subunits, 646  
 auxiliary subunit modulators, 650  
 $\beta$  subunits, 645–646  
 Ca<sub>v</sub>1 family, 647–648  
 Ca<sub>v</sub>2 family, 648–649  
 Ca<sub>v</sub>3 family, 649–650  
 $\gamma$  subunits, 646  
 general blockers, 647  
 miscellaneous channels, 650–651  
 cloning and evolutionary relationships, 619–620  
 nomenclature, 621  
 potassium channels, 621–635  
 calcium activation, 630–632  
 fast inactivation, 627  
 gating, 626–627  
 interacting proteins, 627–628  
 inwardly-rectifying and two-P channels, 634–635  
 KCNH channels, 633–634  
 KCNQ family, 632–633  
 K<sub>v</sub> subunits, 628–630  
 physiology, disease and pharmacology, 628–634  
 selectivity, 623–625  
 voltage activation, 625–626  
 research background, 618–619  
 sodium channels, 635–643  
 $\alpha$  subunits, 636–637  
 channelopathies, 641–642  
 inactivation, 637–638  
 pharmacology, 642–643  
 physiological functions, 639–641  
 selectivity, 637  
 trafficking, 638–639
- Weibel Palade bodies, nitrosylation and, 751
- Willardiines  
 AMPA receptor orthosteric agonists, 376–377  
 kainate receptor orthosteric agonists, 380–381  
 kainate receptor orthosteric antagonists, 384–385
- Zaleplon, GABA<sub>A</sub> subunit pharmacology, allosteric ligand modulation, 504–506
- Ziconotide, voltage-gated calcium ion channels, Ca<sub>v</sub>2 family, 649
- Zolpidem  
 GABA<sub>A</sub> subunit pharmacology  
 allosteric ligand modulation, 504–506  
 benzodiazepine binding sites, 510–511  
 GABA<sub>A</sub> subunit selectivity, 484